{"id": "ryxMek0AAAAJ", "citedby": 39724, "citedby5y": 13193, "hindex": 95, "hindex5y": 51, "i10index": 266, "i10index5y": 176, "coauthors": [], "name": "David P Carbone", "affiliation": "Ohio State University", "interests": ["lung cancer"], "cites_per_year": {"1992": 110, "1993": 215, "1994": 323, "1995": 300, "1996": 316, "1997": 371, "1998": 482, "1999": 543, "2000": 671, "2001": 740, "2002": 878, "2003": 957, "2004": 1242, "2005": 1478, "2006": 1728, "2007": 1737, "2008": 1832, "2009": 1783, "2010": 1833, "2011": 2002, "2012": 2067, "2013": 2190, "2014": 2166, "2015": 2037, "2016": 2147, "2017": 2388, "2018": 2565, "2019": 2679, "2020": 1293}, "publications": [{"bib": {"title": "Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:u5HHmVD_uO8C", "citedby": "2122"}, {"bib": {"title": "Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:u-x6o8ySG0sC", "citedby": "1414"}, {"bib": {"title": "ROS1 rearrangements define a unique molecular class of lung cancers", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:2osOgNQ5qMEC", "citedby": "1384"}, {"bib": {"title": "Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:d1gkVwhDpl0C", "citedby": "1071"}, {"bib": {"title": "First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RtRctb2lSbAC", "citedby": "1028"}, {"bib": {"title": "Mechanism and its regulation of tumor-induced angiogenesis", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:G1UMdFYMoxkC", "citedby": "1018"}, {"bib": {"title": "Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:pQTOvowfQioC", "citedby": "989"}, {"bib": {"title": "Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo \u2026", "year": "1998"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:9yKSN-GCB0IC", "citedby": "978"}, {"bib": {"title": "Overall survival and long-term safety of nivolumab (anti\u2013programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non\u2013small-cell lung cancer", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-f6ydRqryjwC", "citedby": "890"}, {"bib": {"title": "Abrogation of TGF\u03b2 signaling in mammary carcinomas recruits Gr-1+ CD11b+ myeloid cells that promote metastasis", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Tyk-4Ss8FVUC", "citedby": "885"}, {"bib": {"title": "Clinical significance of defective dendritic cell differentiation in cancer", "year": "2000"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:qjMakFHDy7sC", "citedby": "822"}, {"bib": {"title": "NKT cell\u2013mediated repression of tumor immunosurveillance by IL-13 and the IL-4R\u2013STAT6 pathway", "year": "2000"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:IjCSPb-OGe4C", "citedby": "755"}, {"bib": {"title": "Proteomic patterns of tumour subsets in non-small-cell lung cancer", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:UeHWp8X0CEIC", "citedby": "737"}, {"bib": {"title": "Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine \u2026", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:zYLM7Y9cAGgC", "citedby": "642"}, {"bib": {"title": "Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.", "year": "1990"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Y0pCki6q_DkC", "citedby": "640"}, {"bib": {"title": "Delivering affordable cancer care in high-income countries", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_FxGoFyzp5QC", "citedby": "616"}, {"bib": {"title": "Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-\u03baB activation in hemopoietic progenitor cells", "year": "1998"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:eQOLeE2rZwMC", "citedby": "567"}, {"bib": {"title": "p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.", "year": "1992"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:YsMSGLbcyi4C", "citedby": "540"}, {"bib": {"title": "Decreased antigen presentation by dendritic cells in patients with breast cancer.", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:W7OEmFMy1HYC", "citedby": "536"}, {"bib": {"title": "Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ufrVoPGSRksC", "citedby": "487"}, {"bib": {"title": "Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WF5omc3nYNoC", "citedby": "476"}, {"bib": {"title": "VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:3fE2CSJIrl8C", "citedby": "414"}, {"bib": {"title": "VEGF as a mediator of tumor-associated immunodeficiency", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:0EnyYjriUFMC", "citedby": "384"}, {"bib": {"title": "Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation", "year": "1992"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LkGwnXOMwfcC", "citedby": "371"}, {"bib": {"title": "Significance of p63 amplification and overexpression in lung cancer development and prognosis", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hqOjcs7Dif8C", "citedby": "367"}, {"bib": {"title": "Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Se3iqnhoufwC", "citedby": "365"}, {"bib": {"title": "Regulation of mast cell survival by IgE", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:roLk4NBRz8UC", "citedby": "355"}, {"bib": {"title": "Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.", "year": "1992"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:UebtZRa9Y70C", "citedby": "351"}, {"bib": {"title": "Mass spectrometry to classify non\u2013small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a \u2026", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:MXK_kJrjxJIC", "citedby": "327"}, {"bib": {"title": "Dendritic cells in antitumor immune responses: I. Defective antigen presentation in tumor-bearing hosts", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:5nxA0vEk-isC", "citedby": "326"}, {"bib": {"title": "Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions", "year": "1992"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:8k81kl-MbHgC", "citedby": "306"}, {"bib": {"title": "Tumor-host immune interactions and dendritic cell dysfunction", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:KlAtU1dfN6UC", "citedby": "284"}, {"bib": {"title": "\u03b3-Secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:M3ejUd6NZC8C", "citedby": "283"}, {"bib": {"title": "Chromosome 19 translocation, overexpression of Notch3, and human lung cancer", "year": "2000"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4TOpqqG69KYC", "citedby": "280"}, {"bib": {"title": "NCI\u2010navy medical oncology branch cell line data base", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ULOm3_A8WrAC", "citedby": "278"}, {"bib": {"title": "Adenosine receptors in regulation of dendritic cell differentiation and function", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:9ZlFYXVOiuMC", "citedby": "273"}, {"bib": {"title": "Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kNdYIx-mwKoC", "citedby": "269"}, {"bib": {"title": "Spectrum of anemia associated with chronic liver disease", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:nPT8s1NX_-sC", "citedby": "268"}, {"bib": {"title": "PDL1 Regulation by p53 via miR-34", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LI9QrySNdTsC", "citedby": "265"}, {"bib": {"title": "Dendritic cells in antitumor immune responses: II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers \u2026", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Zph67rFs4hoC", "citedby": "263"}, {"bib": {"title": "High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.", "year": "1992"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:YOwf2qJgpHMC", "citedby": "257"}, {"bib": {"title": "Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes.", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_kc_bZDykSQC", "citedby": "233"}, {"bib": {"title": "Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:QIV2ME_5wuYC", "citedby": "220"}, {"bib": {"title": "A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells", "year": "1993"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:qxL8FJ1GzNcC", "citedby": "219"}, {"bib": {"title": "Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4DMP91E08xMC", "citedby": "215"}, {"bib": {"title": "A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Wp0gIr-vW9MC", "citedby": "209"}, {"bib": {"title": "Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors", "year": "1998"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:aqlVkmm33-oC", "citedby": "207"}, {"bib": {"title": "Non-small-cell lung cancer", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:X9ykpCP0fEIC", "citedby": "192"}, {"bib": {"title": "Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:7PzlFSSx8tAC", "citedby": "192"}, {"bib": {"title": "The Mspl polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products", "year": "1991"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:mVmsd5A6BfQC", "citedby": "185"}, {"bib": {"title": "Scientific advances in lung cancer 2015", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hCrLmN-GePgC", "citedby": "164"}, {"bib": {"title": "Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non\u2013small-cell lung cancer", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ZeXyd9-uunAC", "citedby": "161"}, {"bib": {"title": "Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RGFaLdJalmkC", "citedby": "158"}, {"bib": {"title": "Activity of docetaxel in platinum-treated non\u2013small-cell lung cancer: Results of a phase II multicenter trial", "year": "2000"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:dhFuZR0502QC", "citedby": "158"}, {"bib": {"title": "Improving the evaluation of new cancer treatments: challenges and opportunities", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hFOr9nPyWt4C", "citedby": "156"}, {"bib": {"title": "Induction chemotherapy increases perioperative complications in patients undergoing resection for non\u2013small cell lung cancer", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:qUcmZB5y_30C", "citedby": "154"}, {"bib": {"title": "Polymorphism at codon 213 within the p53 gene.", "year": "1991"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hC7cP41nSMkC", "citedby": "153"}, {"bib": {"title": "Immunization with mutant p53-and K-ras-derived peptides in cancer patients: immune response and clinical outcome", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:iH-uZ7U-co4C", "citedby": "150"}, {"bib": {"title": "Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:L8Ckcad2t8MC", "citedby": "149"}, {"bib": {"title": "Smoking and cancer", "year": "1992"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:isC4tDSrTZIC", "citedby": "146"}, {"bib": {"title": "The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation\u2013Positive Non\u2013Small cell lung cancer: status in 2016", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SIv7DqKytYAC", "citedby": "145"}, {"bib": {"title": "Host A2B adenosine receptors promote carcinoma growth", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:NaGl4SEjCO4C", "citedby": "145"}, {"bib": {"title": "A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:e5wmG9Sq2KIC", "citedby": "144"}, {"bib": {"title": "Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:W2uZP3ddy8sC", "citedby": "143"}, {"bib": {"title": "Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer", "year": "1992"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:mB3voiENLucC", "citedby": "139"}, {"bib": {"title": "p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: A preliminary report \u2026", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:IWHjjKOFINEC", "citedby": "137"}, {"bib": {"title": "A training-testing approach to the molecular classification of resected non-small cell lung cancer", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:j3f4tGmQtD8C", "citedby": "133"}, {"bib": {"title": "The importance of inorganic phosphate in regulation of energy metabolism of Streptococcus lactis.", "year": "1981"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HDshCWvjkbEC", "citedby": "130"}, {"bib": {"title": "Targeting cyclooxygenase-2 in recurrent non\u2013small cell lung cancer: a phase II trial of celecoxib and docetaxel", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RHpTSmoSYBkC", "citedby": "127"}, {"bib": {"title": "Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_Qo2XoVZTnwC", "citedby": "127"}, {"bib": {"title": "Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:35N4QoGY0k4C", "citedby": "126"}, {"bib": {"title": "Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:maZDTaKrznsC", "citedby": "125"}, {"bib": {"title": "Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:AzKEL7Gb_04C", "citedby": "124"}, {"bib": {"title": "A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:TQgYirikUcIC", "citedby": "123"}, {"bib": {"title": "Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines", "year": "2002"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:R3hNpaxXUhUC", "citedby": "123"}, {"bib": {"title": "Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BqipwSGYUEgC", "citedby": "121"}, {"bib": {"title": "Thioredoxin-1 Modulates Transcription of Cyclooxygenase-2 via Hypoxia-Inducible Factor-1\u03b1 in Non\u2013Small Cell Lung Cancer", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:bEWYMUwI8FkC", "citedby": "120"}, {"bib": {"title": "A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hMod-77fHWUC", "citedby": "120"}, {"bib": {"title": "Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4JMBOYKVnBMC", "citedby": "119"}, {"bib": {"title": "Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:r0BpntZqJG4C", "citedby": "118"}, {"bib": {"title": "Predictive markers for the efficacy of anti\u2013PD-1/PD-L1 antibodies in lung cancer", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BzfGm06jWhQC", "citedby": "117"}, {"bib": {"title": "Molecular cross-talk between Helicobacter pylori and human gastric mucosa", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:08ZZubdj9fEC", "citedby": "117"}, {"bib": {"title": "Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:eGYfIraVYiQC", "citedby": "116"}, {"bib": {"title": "Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:k_IJM867U9cC", "citedby": "114"}, {"bib": {"title": "Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:JV2RwH3_ST0C", "citedby": "111"}, {"bib": {"title": "Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival", "year": "1993"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:blknAaTinKkC", "citedby": "111"}, {"bib": {"title": "Immunologic dysfunction in cancer.", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:TFP_iSt0sucC", "citedby": "110"}, {"bib": {"title": "Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:YFjsv_pBGBYC", "citedby": "109"}, {"bib": {"title": "Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:GnPB-g6toBAC", "citedby": "105"}, {"bib": {"title": "Analysis of host-and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non\u2013small cell lung \u2026", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:g5m5HwL7SMYC", "citedby": "104"}, {"bib": {"title": "Nuclear survivin as a biomarker for non-small-cell lung cancer", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:M3NEmzRMIkIC", "citedby": "104"}, {"bib": {"title": "Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non\u2013small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials \u2026", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:pyW8ca7W8N0C", "citedby": "100"}, {"bib": {"title": "Proteomic patterns of preinvasive bronchial lesions", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RYcK_YlVTxYC", "citedby": "96"}, {"bib": {"title": "Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:J_g5lzvAfSwC", "citedby": "96"}, {"bib": {"title": "Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ns9cj8rnVeAC", "citedby": "95"}, {"bib": {"title": "Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:xtRiw3GOFMkC", "citedby": "93"}, {"bib": {"title": "The biology of lung cancer.", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:O3NaXMp0MMsC", "citedby": "93"}, {"bib": {"title": "EGFR blockade enriches for lung cancer stem\u2013like cells through Notch3-dependent signaling", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:eMMeJKvmdy0C", "citedby": "91"}, {"bib": {"title": "A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non\u2013small cell lung cancer", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:2P1L_qKh6hAC", "citedby": "91"}, {"bib": {"title": "Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4OULZ7Gr8RgC", "citedby": "90"}, {"bib": {"title": "Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:vV6vV6tmYwMC", "citedby": "90"}, {"bib": {"title": "Integration of molecular profiling into the lung cancer clinic", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HoB7MX3m0LUC", "citedby": "89"}, {"bib": {"title": "Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC)", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:NMxIlDl6LWMC", "citedby": "89"}, {"bib": {"title": "Adenovirus-based p53 gene therapy in ovarian cancer", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:lSLTfruPkqcC", "citedby": "88"}, {"bib": {"title": "Genomics and proteomics: emerging technologies in clinical cancer research", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SeFeTyx0c_EC", "citedby": "86"}, {"bib": {"title": "A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:pqnbT2bcN3wC", "citedby": "85"}, {"bib": {"title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:V3AGJWp-ZtQC", "citedby": "84"}, {"bib": {"title": "Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:P5F9QuxV20EC", "citedby": "84"}, {"bib": {"title": "The molecular basis of lung cancer: molecular abnormalities and therapeutic implications", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:zA6iFVUQeVQC", "citedby": "84"}, {"bib": {"title": "Restoration of TGF-\u03b2 signalling reduces tumorigenicity in human lung cancer cells", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:dfsIfKJdRG4C", "citedby": "83"}, {"bib": {"title": "Immune dysfunction in cancer patients", "year": "2002"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ldfaerwXgEUC", "citedby": "83"}, {"bib": {"title": "Puncture-mediated gene transfer to the skin", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:70eg2SAEIzsC", "citedby": "82"}, {"bib": {"title": "Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non\u2013small-cell lung cancer", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:M05iB0D1s5AC", "citedby": "77"}, {"bib": {"title": "Structural and functional analysis of \u03b22 microglobulin abnormalities in human lung and breast cancer", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ZHo1McVdvXMC", "citedby": "77"}, {"bib": {"title": "Principles and Practice of Lung Cancer: the official reference text of the International Association for the Study of Lung Cancer (IASLC)", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:AXPGKjj_ei8C", "citedby": "72"}, {"bib": {"title": "The molecular genetics of lung cancer", "year": "1992"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:3s1wT3WcHBgC", "citedby": "71"}, {"bib": {"title": "Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:fPk4N6BV_jEC", "citedby": "70"}, {"bib": {"title": "In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4fKUyHm3Qg0C", "citedby": "69"}, {"bib": {"title": "Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:NhqRSupF_l8C", "citedby": "69"}, {"bib": {"title": "Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non\u2013small-cell lung cancer", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:a0OBvERweLwC", "citedby": "69"}, {"bib": {"title": "H1\u00b0 histone and differentiation of dendritic cells. A molecular target for tumor\u2010derived factors", "year": "2002"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:cFHS6HbyZ2cC", "citedby": "69"}, {"bib": {"title": "Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group \u2026", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:f2IySw72cVMC", "citedby": "68"}, {"bib": {"title": "Proteomics analysis in lung cancer: challenges and opportunities", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:rO6llkc54NcC", "citedby": "68"}, {"bib": {"title": "Molecular genetic changes found in human lung cancer and its precursor lesions", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_xSYboBqXhAC", "citedby": "67"}, {"bib": {"title": "VeriStrat\u00ae classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:KxtntwgDAa4C", "citedby": "65"}, {"bib": {"title": "Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A* 0201 peptide consensus motif", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:abG-DnoFyZgC", "citedby": "65"}, {"bib": {"title": "Lung cancer diagnosis from proteomic analysis of preinvasive lesions", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Tiz5es2fbqcC", "citedby": "64"}, {"bib": {"title": "Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN \u2026", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RJOyoaXV5v8C", "citedby": "63"}, {"bib": {"title": "Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:CHSYGLWDkRkC", "citedby": "63"}, {"bib": {"title": "Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tkaPQYYpVKoC", "citedby": "61"}, {"bib": {"title": "Non\u2013small-cell lung cancer: role of the immune system and potential for immunotherapy", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ipzZ9siozwsC", "citedby": "60"}, {"bib": {"title": "Lung cancer vaccines and gene therapy", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:yD5IFk8b50cC", "citedby": "60"}, {"bib": {"title": "IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer.", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:b0M2c_1WBrUC", "citedby": "60"}, {"bib": {"title": "NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv \u2026", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:C33y2ycGS3YC", "citedby": "59"}, {"bib": {"title": "Vascular endothelial growth factor effects on nuclear factor-\u03baB activation in hematopoietic progenitor cells", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:EUQCXRtRnyEC", "citedby": "59"}, {"bib": {"title": "Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors.", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:D03iK_w7-QYC", "citedby": "59"}, {"bib": {"title": "Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:sSrBHYA8nusC", "citedby": "58"}, {"bib": {"title": "Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:wbdj-CoPYUoC", "citedby": "57"}, {"bib": {"title": "Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non\u2013Small-Cell Lung Cancer", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:dshw04ExmUIC", "citedby": "57"}, {"bib": {"title": "Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology", "year": "1991"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:uWQEDVKXjbEC", "citedby": "56"}, {"bib": {"title": "A hybrid computerized fluoroscopy technique for noninvasive cardiovascular imaging", "year": "1979"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:bFI3QPDXJZMC", "citedby": "56"}, {"bib": {"title": "Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SP6oXDckpogC", "citedby": "55"}, {"bib": {"title": "Insulin\u2010like growth factor\u2010I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:u9iWguZQMMsC", "citedby": "54"}, {"bib": {"title": "One size does not fit all", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:K3LRdlH-MEoC", "citedby": "53"}, {"bib": {"title": "A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43\u20139006) in Previously Treated Non\u2013Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology \u2026", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:bnK-pcrLprsC", "citedby": "52"}, {"bib": {"title": "Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:UxriW0iASnsC", "citedby": "52"}, {"bib": {"title": "SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non\u2013small cell lung cancer", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kzcSZmkxUKAC", "citedby": "50"}, {"bib": {"title": "Combination therapy with conditionally replicating adenovirus and replication defective adenovirus", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:nb7KW1ujOQ8C", "citedby": "50"}, {"bib": {"title": "Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:5awf1xo2G04C", "citedby": "49"}, {"bib": {"title": "Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel \u2026", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:1sJd4Hv_s6UC", "citedby": "49"}, {"bib": {"title": "Cytoplasmic Clusterin Expression Is Associated with Longer Survival in Patients with Resected Non\u2013Small Cell Lung Cancer", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:738O_yMBCRsC", "citedby": "49"}, {"bib": {"title": "Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WWeOtg8bX_EC", "citedby": "48"}, {"bib": {"title": "Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WbkHhVStYXYC", "citedby": "48"}, {"bib": {"title": "Defining a standard set of patient-centred outcomes for lung cancer", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:AYInfyleIOsC", "citedby": "47"}, {"bib": {"title": "Effects of Cancer-Associated EPHA3 Mutations on Lung Cancer", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:XiVPGOgt02cC", "citedby": "47"}, {"bib": {"title": "Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:5Ul4iDaHHb8C", "citedby": "47"}, {"bib": {"title": "Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:XiSMed-E-HIC", "citedby": "47"}, {"bib": {"title": "Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, \u2265 3rd line small cell lung cancer: Results from the phase 2 TRINITY study.", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:pYKElYtJMmwC", "citedby": "46"}, {"bib": {"title": "Bortezomib\u00b1docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 study", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:OU6Ihb5iCvQC", "citedby": "46"}, {"bib": {"title": "Cyclooxygenase-2 (COX-2) inhibition+ docetaxel (Txt) in recurrent non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (THO-0054)", "year": "2002"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:v6i8RKmR8ToC", "citedby": "46"}, {"bib": {"title": "Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tS2w5q8j5-wC", "citedby": "44"}, {"bib": {"title": "Cancer of the lung: non-small cell lung cancer and small cell lung cancer", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:u_35RYKgDlwC", "citedby": "44"}, {"bib": {"title": "Expression of angiomodulin (tumor\u2010derived adhesion factor/mac25) in invading tumor cells correlates with poor prognosis in human colorectal cancer", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:l7t_Zn2s7bgC", "citedby": "43"}, {"bib": {"title": "Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:B3FOqHPlNUQC", "citedby": "42"}, {"bib": {"title": "Adjuvant therapy in Non\u2013Small cell lung cancer: future treatment prospects and paradigms", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kRWSkSYxWN8C", "citedby": "42"}, {"bib": {"title": "LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tzM49s52ZIMC", "citedby": "41"}, {"bib": {"title": "Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:s9ia6_kGH2AC", "citedby": "40"}, {"bib": {"title": "Cloned fusion product from a rare t (15; 19)(q13. 2; p13. 1) inhibit S phase in vitro", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:8AbLer7MMksC", "citedby": "39"}, {"bib": {"title": "Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:p2g8aNsByqUC", "citedby": "39"}, {"bib": {"title": "Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:1qzjygNMrQYC", "citedby": "38"}, {"bib": {"title": "Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of \u2026", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SxCCDk4iOpsC", "citedby": "37"}, {"bib": {"title": "Costs of diagnostic assessment for lung cancer: a medicare claims analysis", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ghEM2AJqZyQC", "citedby": "37"}, {"bib": {"title": "Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tOudhMTPpwUC", "citedby": "37"}, {"bib": {"title": "Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:fQNAKQ3IYiAC", "citedby": "36"}, {"bib": {"title": "In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:vRqMK49ujn8C", "citedby": "36"}, {"bib": {"title": "LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:0KyAp5RtaNEC", "citedby": "35"}, {"bib": {"title": "Elucidating the mechanism of regulation of transforming growth factor \u03b2 type II receptor expression in human lung cancer cell lines", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:5ugPr518TE4C", "citedby": "35"}, {"bib": {"title": "Relationship between overall survival and response or progression-free survival in advanced non\u2013small cell lung cancer patients treated with anti\u2013PD-1/PD-L1 antibodies", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:wE-fMHVdjMkC", "citedby": "34"}, {"bib": {"title": "Deletion of IGF-I receptor (IGF-IR) in primary osteoblasts reduces GH-induced STAT5 signaling", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:D_sINldO8mEC", "citedby": "34"}, {"bib": {"title": "Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LPZeul_q3PIC", "citedby": "34"}, {"bib": {"title": "Current status and future perspectives on neoadjuvant therapy in lung cancer", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:9NZAP19TdFAC", "citedby": "33"}, {"bib": {"title": "MALDI\u2010MS derived prognostic protein markers for resected non\u2010small cell lung cancer", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Mojj43d5GZwC", "citedby": "33"}, {"bib": {"title": "Cytochrome P450 expression (CYP) in non-small cell lung cancer", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HE397vMXCloC", "citedby": "32"}, {"bib": {"title": "The inhibitory effect of adenovirus-mediated p16INK4a gene transfer on the proliferation of lung cancer cell line.", "year": "1998"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:geHnlv5EZngC", "citedby": "32"}, {"bib": {"title": "Cancer of the lung: non-small cell lung cancer and small cell lung cancer", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:EYYDruWGBe4C", "citedby": "31"}, {"bib": {"title": "Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BrmTIyaxlBUC", "citedby": "31"}, {"bib": {"title": "Molecular fingerprinting in human lung cancer", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:J-pR_7NvFogC", "citedby": "31"}, {"bib": {"title": "p53 as a target for anti-cancer immunotherapy", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:VOx2b1Wkg3QC", "citedby": "31"}, {"bib": {"title": "Chemotherapy for non-small cell lung cancer", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:eflP2zaiRacC", "citedby": "31"}, {"bib": {"title": "Genetic and immunologic therapies for lung cancer", "year": "2002"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:mvPsJ3kp5DgC", "citedby": "30"}, {"bib": {"title": "Genomic characterization of non\u2013small-cell lung cancer in African Americans by targeted massively parallel sequencing", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:oNZyr7d5Mn4C", "citedby": "29"}, {"bib": {"title": "The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:N5tVd3kTz84C", "citedby": "29"}, {"bib": {"title": "Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:eJXPG6dFmWUC", "citedby": "29"}, {"bib": {"title": "Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes.", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:t6usbXjVLHcC", "citedby": "29"}, {"bib": {"title": "Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:q3oQSFYPqjQC", "citedby": "27"}, {"bib": {"title": "VeriStrat\u00ae has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 \u2026", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:1yQoGdGgb4wC", "citedby": "26"}, {"bib": {"title": "Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:3A3nxV7CjKIC", "citedby": "25"}, {"bib": {"title": "Smoking attenuates transforming growth factor-\u03b2\u2013mediated tumor suppression function through downregulation of Smad3 in lung cancer", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:UHK10RUVsp4C", "citedby": "25"}, {"bib": {"title": "In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WA5NYHcadZ8C", "citedby": "25"}, {"bib": {"title": "Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non\u2013small-cell lung cancer", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:7H_jS4BsgvYC", "citedby": "24"}, {"bib": {"title": "Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal cancers", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:9vf0nzSNQJEC", "citedby": "24"}, {"bib": {"title": "Genetic blockade of the insulin\u2010like growth factor 1 receptor for human malignancy", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PELIpwtuRlgC", "citedby": "24"}, {"bib": {"title": "Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Y5dfb0dijaUC", "citedby": "24"}, {"bib": {"title": "Multivalent forms of the Notch ligand DLL-1 enhance antitumor T-cell immunity in lung cancer and improve efficacy of EGFR-targeted therapy", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ClCfbGk0d_YC", "citedby": "23"}, {"bib": {"title": "The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:dTyEYWd-f8wC", "citedby": "23"}, {"bib": {"title": "EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:olpn-zPbct0C", "citedby": "23"}, {"bib": {"title": "Immunotherapy of head and neck cancer.", "year": "1998"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ye4kPcJQO24C", "citedby": "23"}, {"bib": {"title": "Taxol plus radiation for head and neck cancer.", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WqliGbK-hY8C", "citedby": "23"}, {"bib": {"title": "The biology and molecular genetics of lung cancer", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:JoZmwDi-zQgC", "citedby": "23"}, {"bib": {"title": "Blood-based biomarkers in lung cancer: prognosis and treatment decisions", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LK8CI43ZvvMC", "citedby": "22"}, {"bib": {"title": "Somatic mutation spectrum of non\u2013small-cell lung cancer in African Americans: a pooled analysis", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:edDO8Oi4QzsC", "citedby": "22"}, {"bib": {"title": "Identifying barriers associated with enrollment of patients with lung cancer into clinical trials", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:yB1At4FlUx8C", "citedby": "22"}, {"bib": {"title": "Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin", "year": "2000"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SdhP9T11ey4C", "citedby": "22"}, {"bib": {"title": "Gene therapy for lung cancer", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_B80troHkn4C", "citedby": "22"}, {"bib": {"title": "Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:nPTYJWkExTIC", "citedby": "21"}, {"bib": {"title": "Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BwyfMAYsbu0C", "citedby": "21"}, {"bib": {"title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET\u2013Rearranged Lung Cancers", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:EaFouW7jFu4C", "citedby": "20"}, {"bib": {"title": "On Modeling of Lifetime Data using One-Parameter Akash, Lindley and Exponential Distributions", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:AZju0d2GQJ0C", "citedby": "20"}, {"bib": {"title": "Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:xtoqd-5pKcoC", "citedby": "20"}, {"bib": {"title": "Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:35r97b3x0nAC", "citedby": "20"}, {"bib": {"title": "The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non\u2013small cell lung cancer", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:naSTrk-c4S8C", "citedby": "19"}, {"bib": {"title": "ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:2KloaMYe4IUC", "citedby": "19"}, {"bib": {"title": "Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic \u2026", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kzcrU_BdoSEC", "citedby": "19"}, {"bib": {"title": "The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:j8SEvjWlNXcC", "citedby": "18"}, {"bib": {"title": "Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7-1 via recombinant adenovirus.", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:eq2jaN3J8jMC", "citedby": "18"}, {"bib": {"title": "Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II \u2026", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:h168fVGZblEC", "citedby": "17"}, {"bib": {"title": "Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:qwy9JoKyICEC", "citedby": "17"}, {"bib": {"title": "Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-\u03baB crosstalk", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:YohjEiUPhakC", "citedby": "17"}, {"bib": {"title": "Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study.", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hkOj_22Ku90C", "citedby": "17"}, {"bib": {"title": "Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:vDijr-p_gm4C", "citedby": "16"}, {"bib": {"title": "Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib/placebo in the NCIC clinical trials group BR. 21 trial", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:VL0QpB8kHFEC", "citedby": "16"}, {"bib": {"title": "Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma.", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PR6Y55bgFSsC", "citedby": "16"}, {"bib": {"title": "A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or \u2026", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:uLbwQdceFCQC", "citedby": "15"}, {"bib": {"title": "Molecular staging and pharmacogenomics: Clinical implications: from lab to patients and back", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ZuybSZzF8UAC", "citedby": "15"}, {"bib": {"title": "accepted for publication", "year": "2002"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:URolC5Kub84C", "citedby": "15"}, {"bib": {"title": "Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With \u2026", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:R-LXmdHK_14C", "citedby": "14"}, {"bib": {"title": "Akt kinase-interacting protein 1 signals through CREB to drive diffuse malignant mesothelioma", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tH6gc1N1XXoC", "citedby": "14"}, {"bib": {"title": "Cabozantinib (C), erlotinib (E) or the combination (E+ C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized \u2026", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:FAceZFleit8C", "citedby": "14"}, {"bib": {"title": "Sonic hedgehog pathway expression in non-small cell lung cancer", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:7T2F9Uy0os0C", "citedby": "14"}, {"bib": {"title": "Tumour suppressor Fus1 provides a molecular link between inflammatory response and mitochondrial homeostasis", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:EkHepimYqZsC", "citedby": "14"}, {"bib": {"title": "INSULIN\u2010LIKE GROWTH FACTOR\u2010I RECEPTOR AS A CANDIDATE FOR A NOVEL MOLECULAR TARGET IN GASTROINTESTINAL CANCERS", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:W5xh706n7nkC", "citedby": "14"}, {"bib": {"title": "Role of p63 amplification and overexpression in lung cancer development", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:dQ2og3OwTAUC", "citedby": "14"}, {"bib": {"title": "Increased dose-intensity in small-cell lung cancer: a failed strategy?", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:JQOojiI6XY0C", "citedby": "14"}, {"bib": {"title": "In vivo cytotoxicity assay for assessing immunity", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:NJ774b8OgUMC", "citedby": "14"}, {"bib": {"title": "Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non\u2013Small \u2026", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PQEM9vzQD9gC", "citedby": "13"}, {"bib": {"title": "Histone deacetylase inhibition enhances the antitumor activity of a MEK inhibitor in lung cancer cells harboring RAS mutations", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_AeoHAGD03cC", "citedby": "13"}, {"bib": {"title": "Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non\u2013Small Cell Lung Cancer", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:oPLKW5k6eA4C", "citedby": "13"}, {"bib": {"title": "Treatment patterns for advanced non\u2013small-cell lung cancer after platinum-containing therapy in US community oncology clinical practice", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:jU7OWUQzBzMC", "citedby": "13"}, {"bib": {"title": "Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-uzm3Y7AvW0C", "citedby": "13"}, {"bib": {"title": "Impact of pre-analytical variables on cancer targeted gene sequencing efficiency", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:zGdJYJv2LkUC", "citedby": "12"}, {"bib": {"title": "Insulin\u2010like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ML0RJ9NH7IQC", "citedby": "12"}, {"bib": {"title": "Molecular origins of lung cancer: prospects for personalized prevention and therapy", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:z_wVstp3MssC", "citedby": "12"}, {"bib": {"title": "A phase 2 randomized study of GM-CSF gene-modifled autologous tumor vaccine (CG8123) with and without low-dose cyclophosphamide in advanced stage non-small cell lung cancer (NSCLC)", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ZfRJV9d4-WMC", "citedby": "12"}, {"bib": {"title": "Epidermal growth factor receptor overexpression: the importance of context", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_Ybze24A_UAC", "citedby": "12"}, {"bib": {"title": "Cancer of the Lung: Non\u2013Small Cell Lung Cancer and Small Cell Lung Cancer", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Vno172sVVMwC", "citedby": "11"}, {"bib": {"title": "Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RuPIJ_LgqDgC", "citedby": "11"}, {"bib": {"title": "Disease-related symptoms in advanced non-small-cell lung cancer as measured by the Lung Cancer Subscale of the FACT-L questionnaire: clinically meaningful improvement with \u2026", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Fu2w8maKXqMC", "citedby": "11"}, {"bib": {"title": "Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study.", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:VLnqNzywnoUC", "citedby": "11"}, {"bib": {"title": "Mutations in dominant and recessive oncogenes, and the expression of opioid and nicotine receptors in the pathogenesis of lung cancer", "year": "1991"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:cBPnxVikjH8C", "citedby": "11"}, {"bib": {"title": "Global transcriptome analysis of RNA abundance regulation by ADAR in lung adenocarcinoma", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:c59VksA5Vz4C", "citedby": "10"}, {"bib": {"title": "A transcriptional signature identifies LKB1 functional status as a novel determinant of MEK sensitivity in lung adenocarcinoma", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:isU91gLudPYC", "citedby": "10"}, {"bib": {"title": "Molecular biology of lung cancer", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:L7CI7m0gUJcC", "citedby": "10"}, {"bib": {"title": "Biological considerations in lung cancer", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:YB4bud6kWLwC", "citedby": "10"}, {"bib": {"title": "72 Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tKAzc9rXhukC", "citedby": "10"}, {"bib": {"title": "RB1 and p53 genes", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:1r-w4gtu6w8C", "citedby": "10"}, {"bib": {"title": "Real-time computerized fluoroscopic cardiac imaging", "year": "1979"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:evX43VCCuoAC", "citedby": "10"}, {"bib": {"title": "DLL3: an emerging target in small cell lung cancer", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:vnF2_uLGgtgC", "citedby": "9"}, {"bib": {"title": "The IASLC lung cancer staging project: a renewed call to participation", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:sfnaS5RM6jYC", "citedby": "9"}, {"bib": {"title": "Early stage lung cancer: progress in the last 40 years", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:gsN89kCJA0AC", "citedby": "9"}, {"bib": {"title": "Targeting of Notch3 receptor function for cancer therapy", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-mN3Mh-tlDkC", "citedby": "9"}, {"bib": {"title": "Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset \u2026", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:uJ-U7cs_P_0C", "citedby": "9"}, {"bib": {"title": "Summary report 7th annual targeted therapies of the treatment of lung cancer", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:nrtMV_XWKgEC", "citedby": "9"}, {"bib": {"title": "PDGFR-\u0392 expression in small cell lung cancer patients", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:g3aElNc5_aQC", "citedby": "9"}, {"bib": {"title": "Sociological Studies of Children and Youth", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:NMlhSUseqAsC", "citedby": "9"}, {"bib": {"title": "O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_Re3VWB3Y0AC", "citedby": "9"}, {"bib": {"title": "Oncogenic mutations in ras create HLA-A2. 1 binding peptides but affect their extracellular antigen processing.", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-_dYPAW6P2MC", "citedby": "9"}, {"bib": {"title": "Intensive radiation therapy concurrent with up to 7-week continuous-infusion paclitaxel for locally advanced solid tumors: phase I studies.", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:t7zJ5fGR-2UC", "citedby": "9"}, {"bib": {"title": "Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:QoJ_w57xiyAC", "citedby": "8"}, {"bib": {"title": "Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: two cases and a review of the literature", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:lvd772isFD0C", "citedby": "8"}, {"bib": {"title": "Exosomal RNA based liquid biopsy detection of EML4-ALK in plasma from NSCLC patients", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4hFrxpcac9AC", "citedby": "8"}, {"bib": {"title": "Mass spectrometry profile as a predictor of overall survival benefit after treatment with epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:fEOibwPWpKIC", "citedby": "8"}, {"bib": {"title": "Molecular modalities in the treatment of lung cancer", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:9Nmd_mFXekcC", "citedby": "8"}, {"bib": {"title": "Antioncogenes and human cancer", "year": "1993"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:uc_IGeMz5qoC", "citedby": "8"}, {"bib": {"title": "Potential application of gene therapy to lung cancer", "year": "1993"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:AvfA0Oy_GE0C", "citedby": "8"}, {"bib": {"title": "Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ifOnle78iJkC", "citedby": "7"}, {"bib": {"title": "Notch3-dependent \u03b2-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:KS-xo-ZNxMsC", "citedby": "7"}, {"bib": {"title": "Aquaporin 11 variant associates with kidney disease in type 2 diabetic patients", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kw52XkFRtyQC", "citedby": "7"}, {"bib": {"title": "Profiles in variation: lung carcinogenesis", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:epqYDVWIO7EC", "citedby": "7"}, {"bib": {"title": "Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using matrix-assisted laser desorption/ionization-time of flight mass \u2026", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:XD-gHx7UXLsC", "citedby": "7"}, {"bib": {"title": "Lung Cancer: Early Events, Early Interventions: Conference Summary for the 46th Annual Thomas L. Petty Aspen Lung Conference", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:zLWjf1WUPmwC", "citedby": "7"}, {"bib": {"title": "RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:FsLZdJ3BAzkC", "citedby": "6"}, {"bib": {"title": "Lung cancer patients with germline mutations detected by next-generation sequencing and/or liquid biopsy", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:zUl2_INMlC4C", "citedby": "6"}, {"bib": {"title": "Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non \u2026", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hMsQuOkrut0C", "citedby": "6"}, {"bib": {"title": "VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:vbGhcppDl1QC", "citedby": "6"}, {"bib": {"title": "Proteomic analysis of lung cancer tumors", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4MWp96NkSFoC", "citedby": "6"}, {"bib": {"title": "630. A Phase 2 Randomized Study of GM-CSF Gene-Modified Autologous Tumor Cell Immunotherapy (CG8123) with and without Low-Dose Cyclophosphamide in Advanced Stage Non-Small Cell \u2026", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ILKRHgRFtOwC", "citedby": "6"}, {"bib": {"title": "Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tuHXwOkdijsC", "citedby": "6"}, {"bib": {"title": "Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tz746QTLzJkC", "citedby": "5"}, {"bib": {"title": "Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:n3vGvpFsckwC", "citedby": "5"}, {"bib": {"title": "The effect of forced expression of mutated K\u2010RAS gene on gastrointestinal cancer cell lines and the IGF\u20101R targeting therapy", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-DxkuPiZhfEC", "citedby": "5"}, {"bib": {"title": "Initial results of a prospective, multicenter trial to study inherited lung cancer risk associated with germline EGFR T790M: INHERIT EGFR.", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:zwpXiJ37cpgC", "citedby": "5"}, {"bib": {"title": "A phase I study of nab-paclitaxel (nP) with carboplatin (C) and thoracic radiation (TRT) in patients with locally advanced NSCLC.", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:2v_ZtQDX9iAC", "citedby": "5"}, {"bib": {"title": "Surgical evaluation of the mediastinum", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:CYCckWUYoCcC", "citedby": "5"}, {"bib": {"title": "PL1-01: The epidemiology of lung cancer: what we know and what we need to know", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HGTzPopzzJcC", "citedby": "5"}, {"bib": {"title": "Final results of ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line \u2026", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:uWiczbcajpAC", "citedby": "5"}, {"bib": {"title": "Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent with Radiation Therapy for Locally Advanced Non\u2013Small Cell Lung Cancer", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Z5m8FVwuT1cC", "citedby": "5"}, {"bib": {"title": "IGF-1R blockade strategies in human cancers", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BUYA1_V_uYcC", "citedby": "5"}, {"bib": {"title": "E-14. Tumor proteomic patterns predict classification and tumor behavior in human non-small cell lung cancer", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:sNmaIFBj_lkC", "citedby": "5"}, {"bib": {"title": "P-357 Cyclooxygenase-2 (COX-2) inhibition in advanced non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (THO-0054)", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:p__nRnzSRKYC", "citedby": "5"}, {"bib": {"title": "From clinical and pathologic to molecular staging of lung cancer", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:k8Z6L05lTy4C", "citedby": "5"}, {"bib": {"title": "Methods and compositions using peptide-pulsed dendritic cells for stimulating cytotoxic T lymphocytes specific for tumor cells or virus-infected cells", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:i2xiXl-TujoC", "citedby": "5"}, {"bib": {"title": "Tumor suppressor gene-derived peptide antigens", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:S16KYo8Pm5AC", "citedby": "5"}, {"bib": {"title": "Early allograft function in canine single lung transplant", "year": "1993"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-yGd096yOn8C", "citedby": "5"}, {"bib": {"title": "Comparison of p53 gene mutations in paired primary and metastatic gastric tumor tissues", "year": "1993"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:b1wdh0AR-JQC", "citedby": "5"}, {"bib": {"title": "MA04. 09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:yTLRzDEmwhEC", "citedby": "4"}, {"bib": {"title": "Circulating miRNA and extracellular vesicle containing miRNA as response biomarkers of anti PD-1/PD-L1 therapy in non-small-cell lung cancer.", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hNSvKAmkeYkC", "citedby": "4"}, {"bib": {"title": "Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers.", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:8dzOF9BpDQoC", "citedby": "4"}, {"bib": {"title": "A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:T_ojBgVMvoEC", "citedby": "4"}, {"bib": {"title": "Increased PD-L1 expression in KRAS mutated premalignant human bronchial epithelial cells is enhanced by LKB1 loss and mediated by ERK activation", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:An6A6Jpfc1oC", "citedby": "4"}, {"bib": {"title": "Promise of Immunotherapy in Lung Cancer", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:QYdC8u9Cj1oC", "citedby": "4"}, {"bib": {"title": "Early-stage lung cancer: 40s anniversary", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:__bU50VfleQC", "citedby": "4"}, {"bib": {"title": "A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC).", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:9pM33mqn1YgC", "citedby": "4"}, {"bib": {"title": "Targeting of Notch3 Receptor Function for Cancer Therapy", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:QsKbpXNoaWkC", "citedby": "4"}, {"bib": {"title": "A randomized discontinuation phase II study of sorafenib vs placebo in patients with non-small cell lung cancer (NSCLC) who failed at least two prior chemotherapy regimens: E2501", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:KUbvn5osdkgC", "citedby": "4"}, {"bib": {"title": "Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kuK5TVdYjLIC", "citedby": "4"}, {"bib": {"title": "919 Clinically meaningful improvement in disease-related symptoms by gefitinib ('Iressa', ZD1839) in patients with advanced non-small-cell lung cancer: relationship between \u2026", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:VaXvl8Fpj5cC", "citedby": "4"}, {"bib": {"title": "Concurrent intensive radiotherapy and prolonged continuous-infusion paclitaxel for locally advanced solid tumors: Results of three phase I trials", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:e_rmSamDkqQC", "citedby": "4"}, {"bib": {"title": "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor \u2026", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:uUvzmPk0f8oC", "citedby": "3"}, {"bib": {"title": "Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:VRfTbSk87rEC", "citedby": "3"}, {"bib": {"title": "The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non\u2013Small Cell Lung Cancer", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BmWJbWwHJAwC", "citedby": "3"}, {"bib": {"title": "P1. 01-09 Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS)\u2265 50%: KEYNOTE-598", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RMgMIBzvq-4C", "citedby": "3"}, {"bib": {"title": "Proteogenomic analysis of surgically resected lung adenocarcinoma", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:x21FZCSn4ZoC", "citedby": "3"}, {"bib": {"title": "Non-small cell lung cancer genomics around the globe: focus on ethnicity", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ZqE1mSdD_DYC", "citedby": "3"}, {"bib": {"title": "PS01. 66: biomarker stratification of outcomes of third-generation EGFR TKI therapy in patients with previously-treated advanced NSCLC: Topic: Medical Oncology", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:2ywjKiB__4kC", "citedby": "3"}, {"bib": {"title": "Somatic mutation spectrum of non-small cell lung cancers (NSCLCs) from African Americans (AAs).", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:jgBuDB5drN8C", "citedby": "3"}, {"bib": {"title": "A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC).", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kz9GbA2Ns4gC", "citedby": "3"}, {"bib": {"title": "A phase I/II study of nab-paclitaxel and carboplatin with concurrent radiation therapy for unresectable stage III non-small-cell lung cancer (NSCLC)", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BJbdYPG6LGMC", "citedby": "3"}, {"bib": {"title": "Adenosine A2B receptors in regulation of dendritic cell differentiation and function", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:XoXfffV-tXoC", "citedby": "3"}, {"bib": {"title": "Molecular targeting of IGF-I receptor for human pancreatic cancer", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:TIZ-Mc8IlK0C", "citedby": "3"}, {"bib": {"title": "El distrito industrial y el capital social: Implicaciones en las decisiones de relocalizaci\u00f3n de actividades. El caso de la cer\u00e1mica de Castell\u00f3n. Universitat Jaume I\u2013Castell\u00f3n \u2026", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ijdKiLOsEJMC", "citedby": "3"}, {"bib": {"title": "Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:0N-VGjzr574C", "citedby": "3"}, {"bib": {"title": "Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC)", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WZBGuue-350C", "citedby": "3"}, {"bib": {"title": "Acquired EGFr TKI resistance associated with mutation of the EGFr.", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ruyezt5ZtCIC", "citedby": "3"}, {"bib": {"title": "Oncogenes and tumor suppressor genes", "year": "1993"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:MLfJN-KU85MC", "citedby": "3"}, {"bib": {"title": "Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:sbeIDTyQOFgC", "citedby": "2"}, {"bib": {"title": "Identification of recurrent activating HER2 mutations in primary canine pulmonary adenocarcinoma", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:natZJ_-F0IUC", "citedby": "2"}, {"bib": {"title": "Safety of dose-reduced pemetrexed in patients with renal insufficiency", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:N4u4nq0IxgcC", "citedby": "2"}, {"bib": {"title": "Power restriction period for high efficiency WiFi", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WJVC3Jt7v1AC", "citedby": "2"}, {"bib": {"title": "Co-expression analysis reveals mechanisms underlying the varied roles of NOTCH1 in NSCLC", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:rOcdG6UcVlcC", "citedby": "2"}, {"bib": {"title": "1772P Immune related adverse events across cancer types: Incidence, risk factors and survival", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:I8rxH6phXEkC", "citedby": "2"}, {"bib": {"title": "OA 18.02 The Landscape of Alteration of DNA Integrity-Related Genes and Their Association with Tumor Mutation Burden in Non-Small Cell Lung Cancer", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:jtI9f0ekYq0C", "citedby": "2"}, {"bib": {"title": "Ibuprofen and fatal lung cancer: A brief report of the prospective results from the Third National Health and Nutrition Examination Survey (NHANES III)", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4aZ_i-5WJEQC", "citedby": "2"}, {"bib": {"title": "p53 regulation of PDL1 is mediated through miR-34a", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Ug5p-4gJ2f0C", "citedby": "2"}, {"bib": {"title": "Clinical outcomes and prognostic factors of patients with advanced non-small cell lung treated in clinical trials in Brazil: A single institution experience.", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hsZV8lGYWTMC", "citedby": "2"}, {"bib": {"title": "Cancer therapy by resuscitating Notch immune surveillance", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ODE9OILHJdcC", "citedby": "2"}, {"bib": {"title": "Reducing lung cancer mortality: 2014 update.", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:FPJr55Dyh1AC", "citedby": "2"}, {"bib": {"title": "SERUM PROTEOMIC CLASSIFIER FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH ERLOTINIB AND BEVACIZUMAB IN FIRST LINE: POOLED ANALYSIS OF PHASE II \u2026", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SpbeaW3--B0C", "citedby": "2"}, {"bib": {"title": "Summary of Presentations from the 11th Targeted Therapies for Lung Cancer Meeting; Immunotherapy and Vaccines for Treatment of Lung Cancer", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HbR8gkJAVGIC", "citedby": "2"}, {"bib": {"title": "Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:q3CdL3IzO_QC", "citedby": "2"}, {"bib": {"title": "Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC \u2026", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:foquWX3nUaYC", "citedby": "2"}, {"bib": {"title": "Abrogation of TGF\u00df signaling in mammary carcinomas recruits Gr-1+ CD11b+ myeloid cells that promote metastasis", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:GtLg2Ama23sC", "citedby": "2"}, {"bib": {"title": "Adenosine and A2B adenosine receptor in regulation of dendritic cell differentiation and properties", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Ri6SYOTghG4C", "citedby": "2"}, {"bib": {"title": "Expansion of myeloid immune suppressor cells in Tumor-bearing host directly promotes tumor angiogenesis, tumor growth, and metastasis", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:a3BOlSfXSfwC", "citedby": "2"}, {"bib": {"title": "Validation of proteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3503)", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-FonjvnnhkoC", "citedby": "2"}, {"bib": {"title": "Truncation forms of serum amyloid A contribute to a serum proteomic signature of lung cancer", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:3NQIlFlcGxIC", "citedby": "2"}, {"bib": {"title": "O-155 Combined gene therapy with conditionally replicating adenovirus and replication defective adenovirus improves the efficacy of gene therapy", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:OP4eGU-M3BUC", "citedby": "2"}, {"bib": {"title": "Gene therapy for lung cancer", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:lmc2jWPfTJgC", "citedby": "2"}, {"bib": {"title": "Mutant p53 and ras proteins as immunotherapeutic targets.", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:QVtou7C4vgoC", "citedby": "2"}, {"bib": {"title": "The P53 \u201cknockout\u201d: Gone but not forgotten", "year": "1992"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LO7wyVUgiFcC", "citedby": "2"}, {"bib": {"title": "Focusing in on P53 in hepatocellular carcinoma", "year": "1991"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Dip1O2bNi0gC", "citedby": "2"}, {"bib": {"title": "The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non\u2013Small Cell Lung Cancer", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:EBV337fEn3EC", "citedby": "1"}, {"bib": {"title": "MA11. 11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:q0uBw5dMOAkC", "citedby": "1"}, {"bib": {"title": "Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:JH5k92_tO-AC", "citedby": "1"}, {"bib": {"title": "Risk factors for immunotherapy toxicity among older adults", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:U0iAMwwPxtsC", "citedby": "1"}, {"bib": {"title": "MA05. 01 E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:bVQMTfhMCi4C", "citedby": "1"}, {"bib": {"title": "OA04. 05 chronic inflammation, NSAIDS and the risk of lung cancer death", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SAZ1SQo2q1kC", "citedby": "1"}, {"bib": {"title": "P2. 03b-082 AQP11 as a Novel Factor of Lung Cancer Cell Resistance to Cisplatin: Topic: Biomarkers", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tHtfpZlB6tUC", "citedby": "1"}, {"bib": {"title": "Defining a Standard Set of Patient Centered Outcomes for Patients With Lung Cancer", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:UmS_249rOGwC", "citedby": "1"}, {"bib": {"title": "Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:cK4Rrx0J3m0C", "citedby": "1"}, {"bib": {"title": "Targeting IGF-I receptor for hepatocellular carcinoma", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:uVUOdF_882EC", "citedby": "1"}, {"bib": {"title": "An era of lung cancer iconoclasts", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Br1UauaknNIC", "citedby": "1"}, {"bib": {"title": "Oncogenic ARAF mutation in lung adenocarcinoma", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:7Hz3ACDFbsoC", "citedby": "1"}, {"bib": {"title": "Combined Target Therapy for Igf-I Receptor and Vegf against Human Gastric Cancer", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:5qfkUJPXOUwC", "citedby": "1"}, {"bib": {"title": "Value of a serum proteomic signature in the non-invasive evaluation of lung nodules.", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PyEswDtIyv0C", "citedby": "1"}, {"bib": {"title": "Enrollment of lung cancer patients on clinical trials at an NCI comprehensive cancer center", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:MAUkC_7iAq8C", "citedby": "1"}, {"bib": {"title": "Urine PGE-M to assess prostaglandin E2 (PGE2) levels in non-small cell lung cancer (NSCLC)", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:XvxMoLDsR5gC", "citedby": "1"}, {"bib": {"title": "Inhibition of Notch3 signaling pathway using small interfering peptides induces apoptosis in lung cancer cells.", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:8d8msizDQcsC", "citedby": "1"}, {"bib": {"title": "A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiation therapy for patients with inoperable stage IIIA/B non-small cell lung cancer", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PoWvk5oyLR8C", "citedby": "1"}, {"bib": {"title": "Treatment with IGF-I receptor tyrosine kinase inhibitor, NVP-AEW541, for gastrointestinal carcinomas.", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:anf4URPfarAC", "citedby": "1"}, {"bib": {"title": "Severe intrapulmonary shunting in bronchioloalveolar cell carcinoma corrected by selective pulmonary artery occlusion and palliative tumor resection", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kVjdVfd2voEC", "citedby": "1"}, {"bib": {"title": "ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients \u2026", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:umqufdRvDiIC", "citedby": "1"}, {"bib": {"title": "Proteomic patterns of chemosensitivity in NSCLC cell lines", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:MpfHP-DdYjUC", "citedby": "1"}, {"bib": {"title": "Inhibition of EGFR signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small cell lung cancer", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:86PQX7AUzd4C", "citedby": "1"}, {"bib": {"title": "IGF-I receptor is a molecular target for both esophageal squamous cell carcinoma and adenocarcinoma", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PVjk1bu6vJQC", "citedby": "1"}, {"bib": {"title": "Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kWvqk_afx_IC", "citedby": "1"}, {"bib": {"title": "P-027 Targeting Notch3 pathway in lung cancer using gamma-secretaseinhibitors", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WC23djZS0W4C", "citedby": "1"}, {"bib": {"title": "Biomarkers of response to gefitinib in non-small-cell lung cancer", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:rmuvC79q63oC", "citedby": "1"}, {"bib": {"title": "Urine PGE-M as a marker of intratumoral cyclooxygenase-2 activity in non-small cell lung cancer (NSCLC)", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_FM0Bhl9EiAC", "citedby": "1"}, {"bib": {"title": "Molecular prognostication of lung cancer", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:oTdOBqtIf_kC", "citedby": "1"}, {"bib": {"title": "Dendritic cells (DC) loaded with apoptotic, allogeneic melanoma cells reduce tumor progression and improve survival in a murine immunotherapy model", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:artPoR2Yc-kC", "citedby": "1"}, {"bib": {"title": "Dendritic cells loaded with apoptotic melanoma cells slow tumor growth and improve survival in a murine immunotherapy model", "year": "2002"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:0izLItjtcgwC", "citedby": "1"}, {"bib": {"title": "Dendritic cells transduced with wild type p53 gene elicit potent antitumor immune responses.", "year": "1998"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HtEfBTGE9r8C", "citedby": "1"}, {"bib": {"title": "5th IASLC Lung Tumor Biology Workshop, August 13\u201317, 1996, Ermatingen, Switzerland", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:DUooU5lO8OsC", "citedby": "1"}, {"bib": {"title": "Fifth IASLC lung tumor biology workshop, August 13\u201317, 1996, Ermatingen, Switzerland", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4fGpz3EwCPoC", "citedby": "1"}, {"bib": {"title": "Induction of p53ras specific cellular immunity in patients with common solid tumors", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kh2fBNsKQNwC", "citedby": "1"}, {"bib": {"title": "Erratum: Errata", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:MDX3w3dAD3YC", "citedby": "1"}, {"bib": {"title": "Expression of a mutant P53 epitope fused with the adenovirus E3 leader sequence in tumor-cells overcomes Gamma-Ifn dependence of lysis by p53-specific Ctl", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:a9-T7VOCCH8C", "citedby": "1"}, {"bib": {"title": "Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:8VtEwCQfWZkC", "citedby": "0"}, {"bib": {"title": "Abstract B30: Intratumoral microbes correlate with tumor-infiltrating lymphocytes in lung cancer RNAseq", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PVqtIyvKoSUC", "citedby": "0"}, {"bib": {"title": "Intratumoral microbes correlate with tumor-infiltrating lymphocytes in lung cancer RNAseq.", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:sgsej9ZJWHMC", "citedby": "0"}, {"bib": {"title": "Functional Impairment in Advanced Lung Cancer: Beyond Older Age and Disease Severity", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:tBlTYpvFGQIC", "citedby": "0"}, {"bib": {"title": "Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:DQNrXyjhriIC", "citedby": "0"}, {"bib": {"title": "Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical \u2026", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:oursBaop5wYC", "citedby": "0"}, {"bib": {"title": "New approaches to small cell lung cancer therapy: from the laboratory to the clinic", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:0ngZmJvimKcC", "citedby": "0"}, {"bib": {"title": "Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:cNe27ouKFcQC", "citedby": "0"}, {"bib": {"title": "TTF-1 Positive Primary Small Cell Carcinoma of the Breast: A Case Report and Review of the Literature", "year": "2020"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:gV6rEsy15s0C", "citedby": "0"}, {"bib": {"title": "First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell \u2026", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:V_vSwabWVtYC", "citedby": "0"}, {"bib": {"title": "Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:XAp-VaTZjjwC", "citedby": "0"}, {"bib": {"title": "Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:X4-KO54GjGYC", "citedby": "0"}, {"bib": {"title": "Engineered monomeric JAG1 and multimeric DLL1 Notch ligand constructs enhance antitumor immunity by reducing exhaustion of T-effector memory cells", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SpPTWFSNUtQC", "citedby": "0"}, {"bib": {"title": "THE FITNESS STUDY: THE AGING IMMUNE SYSTEM, TREATMENT RESPONSE, AND FUNCTIONAL DECLINE AMONG OLDER ADULTS WITH LUNG CANCER", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:txeM2kYbVNMC", "citedby": "0"}, {"bib": {"title": "Smoking Status Is Not a Replacement Biomarker for Tumor Mutation Burden in Non-Small Lung Cancer: P1. 04-15", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:u3T1itk59dMC", "citedby": "0"}, {"bib": {"title": "Notch3 and \u03b2-Catenin Are Frequently Co-Expressed in EGFR Mutant NSCLC: P2. 14-19", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:bXQfdp6S9ecC", "citedby": "0"}, {"bib": {"title": "Examination of Lifestyle Factors and Associations with Genetic Mutations in Lung Cancer Cases: P1. 10-11", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:yIeBiWEAh44C", "citedby": "0"}, {"bib": {"title": "Identify Vulnerable Pathways and Improve Treatment Outcomes in LKB1-Deficient Lung Tumors: MA17. 02", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:lK9BDNCuzFgC", "citedby": "0"}, {"bib": {"title": "Tumor Mutation Burden in lung cancer", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BJtnxTr0fRcC", "citedby": "0"}, {"bib": {"title": "P2. 14-19 Notch3 and \u03b2-Catenin Are Frequently Co-Expressed in EGFR Mutant NSCLC", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:g_UdREhPGEoC", "citedby": "0"}, {"bib": {"title": "EP1. 12-38 Retrospective Analysis of Immunotherapy Utilization in Advanced Small Cell Carcinoma at an Academic Cancer Center", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WzTVkKNmPSkC", "citedby": "0"}, {"bib": {"title": "P2. 04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Kqc1aDSOPooC", "citedby": "0"}, {"bib": {"title": "P2. 14-10 Identification of Frequent, Activating HER2 Mutations and HER2 Inhibitor Response and Resistance in Canine Lung Cancer", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:idthP5jqfYAC", "citedby": "0"}, {"bib": {"title": "OA13. 07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:NtCmTCuxid4C", "citedby": "0"}, {"bib": {"title": "P1. 10-11 Examination of Lifestyle Factors and Associations with Genetic Mutations in Lung Cancer Cases", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:as0KMg8qHbkC", "citedby": "0"}, {"bib": {"title": "MA17. 02 Identify Vulnerable Pathways and Improve Treatment Outcomes in LKB1-Deficient Lung Tumors", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:v_tt_AnqfNMC", "citedby": "0"}, {"bib": {"title": "P1. 04-15 Smoking Status Is Not a Replacement Biomarker for Tumor Mutation Burden in Non-Small Lung Cancer", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:M_lZXyI38BkC", "citedby": "0"}, {"bib": {"title": "P1. 01-71 Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RXiHnyRawswC", "citedby": "0"}, {"bib": {"title": "LKB1 loss in lung adenocarcinoma leads to global hypomethylation and altered FOXA binding", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:60iIaj97TE0C", "citedby": "0"}, {"bib": {"title": "Genomic characterization of recurrent small cell lung cancer through research autopsy reveals clonal diversity and candidate driver of chemoresistance", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:KI9T_ytC6pkC", "citedby": "0"}, {"bib": {"title": "Identification of frequent HER2 activating mutations in canine primary pulmonary adenocarcinoma", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:TGkaJS32XoUC", "citedby": "0"}, {"bib": {"title": "PAI1, a \u03b2 catenin transcriptional target, serves as a surrogate biomarker to predict EGFR TKI mediated drug persistence in EGFR mutant NSCLC", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:J3LtWjKFLicC", "citedby": "0"}, {"bib": {"title": "Initiation of targeted therapy based on ctDNA only in metastatic NSCLC.", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PuOEWVtPfzwC", "citedby": "0"}, {"bib": {"title": "Is immunotherapy toxicity associated with improved overall survival among older adults with advanced cancer?", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BAanoTsO0WEC", "citedby": "0"}, {"bib": {"title": "Re-evaluating the neutrophil-to-lymphocyte ratio: Machine learning-based variable selection for predicting survival at twelve months in late-stage cancer patients receiving \u2026", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:eH23hyXCXa4C", "citedby": "0"}, {"bib": {"title": "Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial.", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:E7VqQtBCVmcC", "citedby": "0"}, {"bib": {"title": "Novel mechanism of resistance to targeted therapies in lung cancer", "year": "2019"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:wyM6WWKXmoIC", "citedby": "0"}, {"bib": {"title": "Racial/Ethnic Disparities in the Delivery of Curative Intent Therapy in Patients with Stage III Non-small Cell Lung Cancer Not Treated Surgically: An Analysis of the National \u2026", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:YPNY0knpFBYC", "citedby": "0"}, {"bib": {"title": "P3. 01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:xGWFX6Gbr9MC", "citedby": "0"}, {"bib": {"title": "P3. 17-20 Impact of Significant Primary Tumor Size Reduction on Radiation Dose to Normal Structures in Patients Receiving Definitive Chemoradiotherapy", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:3_LpOwP6eMYC", "citedby": "0"}, {"bib": {"title": "P3. 16-06 Does Comprehensive Mutation Analysis Add Prognostic Value in Resected Early Stage Lung Adenocarcinoma?", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:H7nrzBkawXsC", "citedby": "0"}, {"bib": {"title": "MA04. 10 Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:TesyEGJKHF4C", "citedby": "0"}, {"bib": {"title": "P1. 01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:yeL6HyUMUGUC", "citedby": "0"}, {"bib": {"title": "Abstract IA20: Immunotherapy: Biomarkers and checkpoint blockade in NSCLC", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:L24QuVWYgZ0C", "citedby": "0"}, {"bib": {"title": "Aquaporin 11 as a new predictive biomarker of overall survival and platinum-based chemotherapy response in lung adenocarcinoma patients", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Azgs6IHzeyYC", "citedby": "0"}, {"bib": {"title": "The efficacy of a histone deacetylase inhibitor in combination with a MEK inhibitor in lung cancer cells harboring RAS mutations", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:7Frjd3zlGBUC", "citedby": "0"}, {"bib": {"title": "NOTCH1 co-expression analysis reveals novel insights underlying its opposing effects as an oncogenic and tumor suppressor in lung cancer", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:xm0LlTxljI0C", "citedby": "0"}, {"bib": {"title": "Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: A systematic review.", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:M0leSnx2MbUC", "citedby": "0"}, {"bib": {"title": "A cell cycle-related RNA expression signature of neoantigen burden in lung adenocarcinoma.", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:9DLIHnF0jcYC", "citedby": "0"}, {"bib": {"title": "Identification and characterization of germline pathogenic variants using matched tumor-normal next-generation sequencing in 7363 pan-cancer patients in China.", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:jlhcAiayVhoC", "citedby": "0"}, {"bib": {"title": "PV-0040: Patterns of care for the elderly with non-surgically treated stage III non-small cell lung cancer", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WwIwg2wKZ0QC", "citedby": "0"}, {"bib": {"title": "214O Multiplexed proteomics biomarkers for malignant pleural mesothelioma detection in blood", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:qmtmRrLr0tkC", "citedby": "0"}, {"bib": {"title": "Genomics and immunotherapy in lung cancer: tumor mutation burden, mutations affecting antigen presentation, immune recognition, and genome integrity", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:eI34FqJmdUoC", "citedby": "0"}, {"bib": {"title": "Notch in Lung Cancer", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:KTwcwpFFj4wC", "citedby": "0"}, {"bib": {"title": "Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BOlwja0KXvYC", "citedby": "0"}, {"bib": {"title": "Abstract A112: RanBP9 protects cells from genotoxic stress and increased expression is predictive of worse response to platinum in NSCLC patients", "year": "2018"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:OzeSX8-yOCQC", "citedby": "0"}, {"bib": {"title": "P3. 03-002 Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:i_7YvbSbtFEC", "citedby": "0"}, {"bib": {"title": "RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ukw-9cB-YDkC", "citedby": "0"}, {"bib": {"title": "LKB1 Loss Is Associated with DNA Hypomethylation in Human Lung Adenocarcinoma", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4n0clTBhZ78C", "citedby": "0"}, {"bib": {"title": "Lung Cancer Patients with Germline Mutation: A Retrospective Study: MA 06.08", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:qsWQJNntlusC", "citedby": "0"}, {"bib": {"title": "Dual Role of Notch in Lung Cancer: P1. 02-019", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PlWzFYVEG4EC", "citedby": "0"}, {"bib": {"title": "P2. 06-008 Diagnosis of Incidental Disease in Medicaid Recipients During Lung Cancer Screening", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Ic1VZgkJnDsC", "citedby": "0"}, {"bib": {"title": "P1. 02-019 Dual Role of Notch in Lung Cancer", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:c_xDhezhKKUC", "citedby": "0"}, {"bib": {"title": "P1. 09-001 Multiplexed Biomarker Strategies Based on Targeted Proteomics for Detection of Malignant Pleural Mesothelioma in Blood", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:37UQlXuwjP4C", "citedby": "0"}, {"bib": {"title": "MA 06.08 Lung Cancer Patients with Germline Mutation: A Retrospective Study", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:lYAcb2jw7qUC", "citedby": "0"}, {"bib": {"title": "P2. 02-067 LKB1 Loss Is Associated with DNA Hypomethylation in Human Lung Adenocarcinoma", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:nqdriD65xNoC", "citedby": "0"}, {"bib": {"title": "P2. 02-065 RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:X0DADzN9RKwC", "citedby": "0"}, {"bib": {"title": "1617PDMultiplexed targeted proteomics signature for serum diagnostic of malignant pleural mesothelioma", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hQUaER0FWQ4C", "citedby": "0"}, {"bib": {"title": "Reagents Based on Notch Ligands as a Novel Type of Immunotherapeutics", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LGlY6t8CeOMC", "citedby": "0"}, {"bib": {"title": "Notch3-Dependent \u03b2-Catenin Signaling Mediates EGFR TKI Drug Persistence in EGFR Mutant NSCLC", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:YTuZlYwrTOUC", "citedby": "0"}, {"bib": {"title": "Effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibitor in non-small-cell lung cancer", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:QaSi33NTfwYC", "citedby": "0"}, {"bib": {"title": "Expression of aquaporin 11 as a potential predictor of cisplatin sensitivity", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hGdtkIFZdKAC", "citedby": "0"}, {"bib": {"title": "NOTCH ligand-based therapeutics for immunomodulation in cancer and organ transplantation", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BJrgspguQaEC", "citedby": "0"}, {"bib": {"title": "Randomized, open-label phase Ib/II study of atezolizumab with or without daratumumab in previously treated advanced or metastatic non-small cell lung cancer (NSCLC).", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hvmnpdAuIbkC", "citedby": "0"}, {"bib": {"title": "P2. 01-092 PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy: Topic: Targets for \u2026", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:MIg0yeAD4ggC", "citedby": "0"}, {"bib": {"title": "P2. 03b-069 LKB1 Loss is a Novel Determinant of MEK Sensitivity Due to Alterations in AKT/FOXO3 Signaling: Topic: Biomarkers", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:z6xuaG2dYH0C", "citedby": "0"}, {"bib": {"title": "P3. 03-008 Hypoxia-Induced Changes in microRNA Levels Contribute to Drug Resistance in a 3D Model of Malignant Pleural Mesothelioma: Topic: Mesothelioma Transitional", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-6RzNnnwWf8C", "citedby": "0"}, {"bib": {"title": "P2. 04-027 Targeting Adenosine A2B Receptor for Modulation of Tumor Microenvironment, Primary Tumor Growth, and Lung Metastasis: Topic: Esophageal Cancer and Other Malignancies", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:D_tqNUsBuKoC", "citedby": "0"}, {"bib": {"title": "MA16. 03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers", "year": "2017"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:L_l9e5I586QC", "citedby": "0"}, {"bib": {"title": "Loss of LKB1 in NSCLC confers sensitivity to MEK inhibition by regulating activation of AKT-FOXO3 pathway", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kJDgFkosVoMC", "citedby": "0"}, {"bib": {"title": "Dysregulation of lung developmental pathways associated with LKB1 loss in lung cancer", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:zdjWy_NXXwUC", "citedby": "0"}, {"bib": {"title": "First-line treatment of metastatic NSCLC (mNSCLC) patients without actionable mutations in US community oncology clinical practice.", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SGW5VrABaM0C", "citedby": "0"}, {"bib": {"title": "Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:QUX0mv85b1cC", "citedby": "0"}, {"bib": {"title": "Abstract A47: Chromatin remodeling factor SMARCA4 as a predictive biomarker of cisplatin therapy in non-small cell lung cancer", "year": "2016"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:6ZxmRoH8BuwC", "citedby": "0"}, {"bib": {"title": "Effects of introduction of obesity-specific interventions in a state-of-the-art pulmonary rehabilitation programme", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:27LrP4qxOz0C", "citedby": "0"}, {"bib": {"title": "Aki1 as a Potential Therapeutics Target in CREB1 Signaling in Malignant Mesothelioma", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:jSAVyFp_754C", "citedby": "0"}, {"bib": {"title": "Spectrum of Cancer Types in Kindreds with NSCLC and EGFR T790M Mutations: Results from INHERIT EGFR", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:raTqNPD5sRQC", "citedby": "0"}, {"bib": {"title": "SMARCA4/BRG1 Is a Biomarker for Predicting Efficacy of Cisplatin-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RoXSNcbkSzsC", "citedby": "0"}, {"bib": {"title": "Whole Transcriptome Analysis of EGFR Wildtype Non-Small Cell Lung Cancer Patients with Clinical Benefit from Erlotinib", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:NDuN12AVoxsC", "citedby": "0"}, {"bib": {"title": "Treatment Patterns and Overall Survival for Advanced NSCLC Following Platinum-Based Chemotherapy in US Community Oncology Clinical Practice", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:q-HalDI95KYC", "citedby": "0"}, {"bib": {"title": "Mutant ARAF Drives Lung Carcinogenesis Through a Distinct Oncogenic Mechanism", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:v1_lew4L6wgC", "citedby": "0"}, {"bib": {"title": "ERK Activation Mediates Increased PD-L1 Expression in KRAS Mutated Premalignant Human Bronchial Epithelial Cells", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:buQ7SEKw-1sC", "citedby": "0"}, {"bib": {"title": "A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:jL-93Qbq4QoC", "citedby": "0"}, {"bib": {"title": "The effect of forced expression of k-ras mutation on gastrointestinal cancer cells and IGF-IR targeting therapy", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:pAkWuXOU-OoC", "citedby": "0"}, {"bib": {"title": "Alterations in chromatin remodeling pathways as a predictive biomarker of cisplatin therapy in non-small cell lung cancer", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-95Q15plzcUC", "citedby": "0"}, {"bib": {"title": "Akt kinase-interacting protein1 as a potential therapeutics target in CREB1 signaling in malignant pleural mesothelioma", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:QD3KBmkZPeQC", "citedby": "0"}, {"bib": {"title": "Combined inhibition of MEK and PI3K elicits anti-tumor activity in human cholangiocarcinoma", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:IUKN3-7HHlwC", "citedby": "0"}, {"bib": {"title": "Expression of PAK1 and PAK2 Is Associated With Grade of Pulmonary Neuroendocrine Tumors", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:IRz6iEL74y4C", "citedby": "0"}, {"bib": {"title": "Implications of Genomic Heterogeneity in Lung Cancer", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:rHJHxKgnXwkC", "citedby": "0"}, {"bib": {"title": "Early-Stage Lung Cancer: 40s Anniversary (vol 9, pg 1434, 2014)", "year": "2015"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ubry08Y2EpUC", "citedby": "0"}, {"bib": {"title": "Bortezomib enhances anti-tumor T cell immunity by remodeling Notch system", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:AHdEip9mkN0C", "citedby": "0"}, {"bib": {"title": "LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small cell lung cancer (NSCLC) cells", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:hSRAE-fF4OAC", "citedby": "0"}, {"bib": {"title": "FROM BENCH TO BED, FROM SINGLE GENE TO MULTIPLEX ANALYSIS, AND CHALLENGES AND ACCOMPLISHMENTS IN FIGHTING LUNG CANCER", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:EPG8bYD4jVwC", "citedby": "0"}, {"bib": {"title": "Cancer therapy by resuscitating Notch immune surveillance", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:zCSUwVk65WsC", "citedby": "0"}, {"bib": {"title": "Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:NyGDZy8z5eUC", "citedby": "0"}, {"bib": {"title": "Pharmacological stimulation of DLL1-Notch signaling as an effective cancer immunotherapy", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:sJsF-0ZLhtgC", "citedby": "0"}, {"bib": {"title": "Highlights from the latest articles in lung cancer personalized medicine", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:TlpoogIpr_IC", "citedby": "0"}, {"bib": {"title": "Oncogenic ARAF as a new driver in lung adenocarcinoma.", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Bg7qf7VwUHIC", "citedby": "0"}, {"bib": {"title": "Genomic characterization of non-small cell lung cancer by targeted massively parallel sequencing in African Americans.", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:yMeIxYmEMEAC", "citedby": "0"}, {"bib": {"title": "Serum Proteomic Biomarkers", "year": "2014"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:69ZgNCALVd0C", "citedby": "0"}, {"bib": {"title": "Cancer therapy by restoration of immune Notch", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:kF1pexMAQbMC", "citedby": "0"}, {"bib": {"title": "Abstract C90: Dependence of afatinib and cetuximab resistant lung adenocarcinomas on mTOR signaling.", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:QyXJ3EUuO1IC", "citedby": "0"}, {"bib": {"title": "LKB1 LOSS INDUCES CHARACTERISTIC PATHWAY ACTIVATION IN HUMAN TUMORS AND CONFERS SENSITIVITY TO MEK INHIBITION DUE TO ATTENUATED PI3K-AKT-FOXO3 SIGNALING", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:1yWc8FF-_SYC", "citedby": "0"}, {"bib": {"title": "A PROSPECTIVE INTERNET-BASED STUDY OF PATIENTS WITH LUNG CANCER HARBORING BASELINE EGFR T790M TO IDENTIFY GERMLINE CARRIERS AND CHARACTERIZE FAMILIAL RISK", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:prdVHNxh-e8C", "citedby": "0"}, {"bib": {"title": "Abstract C139: Oncogenic ARAF mutation in a metastatic lung adenocarcinoma from a patient exhibiting sustained sorafenib response.", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PYBJJbyH-FwC", "citedby": "0"}, {"bib": {"title": "KDR (VEGFR-2) COPY NUMBER GAINS AND MUTATIONS ARE TARGETABLE ALTERATIONS IN NON-SMALL CELL LUNG CANCER", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:U4n9YNQMCAIC", "citedby": "0"}, {"bib": {"title": "EGFR BLOCKADE INCREASES LUNG CANCER STEM CELL-LIKE CELLS BY UPREGULATION OF NOTCH3 SIGNALING.", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:u-coK7KVo8oC", "citedby": "0"}, {"bib": {"title": "Detection ofALKmutations in crizotinib-resistant non-small-cell lung cancer: moving the field into the next generation", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:qE4H1tSSYIIC", "citedby": "0"}, {"bib": {"title": "Research Highlights: Highlights from the latest articles in translating genomics to clinical practice in lung cancer", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Wq2b2clWBLsC", "citedby": "0"}, {"bib": {"title": "From the Guest Editors: Management of Locally Advanced Lung Cancer", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ziOE8S1-AIUC", "citedby": "0"}, {"bib": {"title": "Resuscitating immune surveillance in cancer.", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-nhnvRiOwuoC", "citedby": "0"}, {"bib": {"title": "IGF-I receptor targeting therapy for esophageal carcinomas.", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:nRpfm8aw39MC", "citedby": "0"}, {"bib": {"title": "LKB1 loss leads to activation of the CREB transcription factor and sensitivity to MEK inhibition in human lung cancer.", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:1lhNe0rCu4AC", "citedby": "0"}, {"bib": {"title": "KDR amplification in NSCLC is associated with sensitivity to VEGFR tyrosine kinase inhibitors.", "year": "2013"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:2tRrZ1ZAMYUC", "citedby": "0"}, {"bib": {"title": "Abstract B93: Resuscitating cancer immunosurveillance by combining Notch 1 and death receptor-activating therapy.", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:silx2ntsSuwC", "citedby": "0"}, {"bib": {"title": "TUMOR SUPPRESSOR FUS1 PROVIDES A MOLECULAR LINK BETWEEN INFLAMMATORY RESPONSE AND MITOCHONDRIAL HOMEOSTASIS", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:OBSaB-F7qqsC", "citedby": "0"}, {"bib": {"title": "A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients.", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4X0JR2_MtJMC", "citedby": "0"}, {"bib": {"title": "Enhancing cancer immunotherapy by combining Notch 1 and death receptor activation (46.38)", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:yxmsSjX2EkcC", "citedby": "0"}, {"bib": {"title": "IGF-I receptor expression is associated with stage and has therapeutic activity in human biliary tract cancers", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:2VqYfGB8ITEC", "citedby": "0"}, {"bib": {"title": "Abstract A9: Pharmacological stimulation of DLL1-Notch signaling as an antitumor immunotherapy", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:wvYxNZNCP7wC", "citedby": "0"}, {"bib": {"title": "Serum Proteomic Classifier for patients with advanced NSCLC treated with Erlotinib and bevacizumab in first line", "year": "2012"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Vr2j17o0sqMC", "citedby": "0"}, {"bib": {"title": "Therapeutic Implications of Targeting of the Sonic Hedgehog Pathway in Non-small Cell Lung Cancer", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:5icHVeHT4IsC", "citedby": "0"}, {"bib": {"title": "Abstract B108: Combining Notch immunostimulation and bortezomib with adoptive immunotherapy in breast cancer", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:6_hjMsCP8ZoC", "citedby": "0"}, {"bib": {"title": "Translating Cancer Complexity to Clinical Decisions", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LhH-TYMQEocC", "citedby": "0"}, {"bib": {"title": "ALDH7A1 expression is associated with recurrence in patients with resected non-small cell lung carcinoma", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:JTqpx9DYBaYC", "citedby": "0"}, {"bib": {"title": "Identification and validation of galectin-7 as a novel blood biomarker for NSCLC diagnosis", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-7ulzOJl1JYC", "citedby": "0"}, {"bib": {"title": "The efficacy of IGF-I receptor monoclonal antibody for human gastrointestinal carcinomas is independent for mutation status of k-ras", "year": "2011"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:gVv57TyPmFsC", "citedby": "0"}, {"bib": {"title": "Modulation of the Sonic Hedgehog Signaling Pathway in Non-small Cell Lung Cancer Targets Stem Cell-like Cancer Cells", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Ade32sEp0pkC", "citedby": "0"}, {"bib": {"title": "Moving a proteomic diagnostic from a clinical need to postmarketing validation", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:FiDNX6EVdGUC", "citedby": "0"}, {"bib": {"title": "EphA3 receptor suppresses tumorigenicity in non-small cell lung cancer through mTOR pathway", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:dBIO0h50nwkC", "citedby": "0"}, {"bib": {"title": "Eicosanoids in non-small cell lung cancer (NSCLC).", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:sszUF3NjhM4C", "citedby": "0"}, {"bib": {"title": "Combined blockade of IGF-I receptor and VEGF for gastric cancer", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:pS0ncopqnHgC", "citedby": "0"}, {"bib": {"title": "The role of Notch and Delta-like 1 in antitumor immunity", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:1DsIQWDZLl8C", "citedby": "0"}, {"bib": {"title": "Predicting lung cancer risk based on a novel proteomic signature of bronchial lesions", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:uDGL6kOW6j0C", "citedby": "0"}, {"bib": {"title": "Development of therapeutic antibodies targeting Notch3 in lung cancer", "year": "2010"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:OcBU2YAGkTUC", "citedby": "0"}, {"bib": {"title": "Prediction of Benefit from EGFR TKIs by Proteomic Analysis of Pre-treatment Serum", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:w1MjKQ0l0TYC", "citedby": "0"}, {"bib": {"title": "Serum mass spectrometry profiling of cancer patients treated with epidermal growth factor receptor inhibitors", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:mKu_rENv82IC", "citedby": "0"}, {"bib": {"title": "Shotgun proteomic analysis of non-small cell lung cancer tissue", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:owLR8QvbtFgC", "citedby": "0"}, {"bib": {"title": "Enrollment of lung cancer patients on clinical trials at an NCI comprehensive cancer center", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WHdLCjDvYFkC", "citedby": "0"}, {"bib": {"title": "Mechanism of vascular endothelial growth factor blockade induced myelosupression in lung cancer patients treated with anti-VEGF therapy", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PaBasH6fAo0C", "citedby": "0"}, {"bib": {"title": "Mining the Proteome for Clinically Useful Lung Cancer Signatures", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4xDN1ZYqzskC", "citedby": "0"}, {"bib": {"title": "Use of biomarker response to celecoxib to predict radiation induced lung and esophageal toxicity: a strategy to individualize thoracic radiation therapy", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:F1b5ZUV5XREC", "citedby": "0"}, {"bib": {"title": "Peptides and recombinant proteins as strategy for targeting Notch3 in lung cancer", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:5MTHONV0fEkC", "citedby": "0"}, {"bib": {"title": "Blood-based CHRNA3 single nucleotide polymorphisms (SNPs) and outcome in advanced non-small cell lung cancer (NSCLC) patients (p)", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Aul-kAQHnToC", "citedby": "0"}, {"bib": {"title": "Abstract# 796: Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:sA9dB-pw3HoC", "citedby": "0"}, {"bib": {"title": "Abstract# 2746: Fc fusion proteins with Notch3 ligand binding regions inhibit human non_small cell lung cancers tumorigenesis", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:FiytvqdAVhgC", "citedby": "0"}, {"bib": {"title": "The aim of Cancer Immunology Immunotherapy is the communication of significant research documented by accurate, unambiguous data that are presented in an easily readable form \u2026", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:wSy_KLzO7YEC", "citedby": "0"}, {"bib": {"title": "Acknowledgment to Reviewers", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:H_jBuBxbQIAC", "citedby": "0"}, {"bib": {"title": "SP141 Serum proteomics in lung cancer", "year": "2009"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:DyXnQzXoVgIC", "citedby": "0"}, {"bib": {"title": "Notch3 modulates apoptosis through the regulation of Bim protein.", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LXmCCkuhhTsC", "citedby": "0"}, {"bib": {"title": "Role of A2B adenosine receptors in tumor growth", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HJSXoJQnj-YC", "citedby": "0"}, {"bib": {"title": "Adenosine A2B receptors on host immune cells promote carcinoma growth", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:jFemdcug13IC", "citedby": "0"}, {"bib": {"title": "IGF-I receptor is a candidate molecular target for human pancreatic cancer", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LdasjJ6CEcoC", "citedby": "0"}, {"bib": {"title": "Mass spectrometric verification of protein biomarker candidates in lung cancer", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Ak0FvsSvgGUC", "citedby": "0"}, {"bib": {"title": "Prediction of sensitivity to chemotherapy in NSCLC using protein expression profiles", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HeT0ZceujKMC", "citedby": "0"}, {"bib": {"title": "Shotgun proteomic analysis of non-small cell lung cancer", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:OTTXONDVkokC", "citedby": "0"}, {"bib": {"title": "Verification of lung cancer protein biomarker candidates using a label free quantification mass spectrometric approach", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:0sTkTiv_uMkC", "citedby": "0"}, {"bib": {"title": "Mass spectrometric verification of lung cancer protein biomarker candidates in lung tissue specimens", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:xyvS_IvSCKsC", "citedby": "0"}, {"bib": {"title": "The aim of Cancer Immunology Immunotherapy is the communication of significant research documented by accurate, unambiguous data that are presented in an easily readable form \u2026", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:8Xgff_V0N9gC", "citedby": "0"}, {"bib": {"title": "Treatment with a New IGF-I Receptor Tyrosine Kinase Inhibitor for Human Colorectal Carcinomas", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:mWEH9CqjF64C", "citedby": "0"}, {"bib": {"title": "Molecular Profiling for Early Detection and Prediction of Response in Lung Cancer", "year": "2008"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:r_AWSJRzSzQC", "citedby": "0"}, {"bib": {"title": "Targeted quantitation of lung cancer biomarker candidates by liquid chromatography-tandem mass spectrometry with multiple reaction monitoring", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:uAPFzskPt0AC", "citedby": "0"}, {"bib": {"title": "Advances and Challenges in Aerodigestive Epithelial Cancer: Meeting Summary and Research Opportunities", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WAzi4Gm8nLoC", "citedby": "0"}, {"bib": {"title": "A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC)", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:YsrPvlHIBpEC", "citedby": "0"}, {"bib": {"title": "Notch signaling mediates the effect of tumor-derived VEGF on lymphoid cell development in vivo", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:-jrNzM816MMC", "citedby": "0"}, {"bib": {"title": "Secretase-inhibitors induce apoptosis and suppress growth of notch3 expressed lung cancer cells.", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LPtt_HFRSbwC", "citedby": "0"}, {"bib": {"title": "A novel role of myeloid related protein in dendritic cell differentiation (49.11)", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_5tno0g5mFcC", "citedby": "0"}, {"bib": {"title": "Verification of lung cancer biomarker candidates by liquid chromatography-tandem mass spectrometry with multiple reaction monitoring (MRM)", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:3lUAU8Oskd0C", "citedby": "0"}, {"bib": {"title": "S8 Value of FDG-PET as a marker of treatment response", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:6VlyvFCUEfcC", "citedby": "0"}, {"bib": {"title": "Jun Konishi, Keiko S. Kawaguchi, Huan Vo, Nobuhiro Haruki, 3 Adriana Gonzalez, 2", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:EsEWqaRxkBgC", "citedby": "0"}, {"bib": {"title": "IGF-I receptor is a candidate molecular target for both human esophageal squamous cell carcinoma and adenocarcinoma", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:jE2MZjpN3IcC", "citedby": "0"}, {"bib": {"title": "S18 Mining the proteome for clinically useful lung cancer signatures: Technology and trade-offs", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:j7_hQOaDUrUC", "citedby": "0"}, {"bib": {"title": "P81 Targeted quantitation of lung cancer biomarker candidates by liquid chromatography\u2013tandem mass spectrometry with multiple reaction monitoring", "year": "2007"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:bKqednn6t2AC", "citedby": "0"}, {"bib": {"title": "221: Use of Aromatase Inhibitors as Radiosensitizing and Therapeutic Agents in the Treatment of Human Pancreatic, Glioblastoma and Lung Cancer", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:65Yg0jNCQDAC", "citedby": "0"}, {"bib": {"title": "2644: Use of Aromatase Inhibitors as Radiosensitizing and Therapeutic Agents in the Treatment of Human Pancreatic, Glioblastoma and Lung Cancer", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:eO3_k5sD8BwC", "citedby": "0"}, {"bib": {"title": "Lung Cancer: Principles and Practice", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:F9fV5C73w3QC", "citedby": "0"}, {"bib": {"title": "VEGF receptor 2 plays major in vivo role in aberrant hematopoiesis in cancer", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:w0F2JDEymm0C", "citedby": "0"}, {"bib": {"title": "The Notch3 contributes to lung tumorigenesis through the modulation of apoptosis and mitogen-activated protein kinase pathway", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:IaI1MmNe2tcC", "citedby": "0"}, {"bib": {"title": "Serum proteomic profiles for predicting response to gefitinib, a cross-laboratory technical validation study", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:8xutWZnSdmoC", "citedby": "0"}, {"bib": {"title": "BOOKS, FILMS, TAPES, & SOFTWARE-Lung Cancer: Principles and Practice", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:sJPMR1oEGYQC", "citedby": "0"}, {"bib": {"title": "A Novel High Throughput MD-MALDI-Tof Platform for Serum Biomarker Discovery", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:L1USKYWJimsC", "citedby": "0"}, {"bib": {"title": "IGF-I receptor as a marker for prognosis and a therapeutic target in esophageal squamous cell carcinoma", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:0CzhzZyukY4C", "citedby": "0"}, {"bib": {"title": "Combination treatment with the dominant negative for IGF-I receptor and chemotherapy for gastrointestinal cancers.", "year": "2006"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:DJbcl8HfkQkC", "citedby": "0"}, {"bib": {"title": "Proteomic strategies for the early detection of lung cancer", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:KbBQZpvPDL4C", "citedby": "0"}, {"bib": {"title": "Proteomics of lung cancer", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4vMrXwiscB8C", "citedby": "0"}, {"bib": {"title": "Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:1Ye0OR6EYb4C", "citedby": "0"}, {"bib": {"title": "P-778 A phase II trial of carboplatin and irinotecan as first-line therapy for extensive stage small cell lung cancer (ES-SCLC): Preliminary results", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:BrOSOlqYqPUC", "citedby": "0"}, {"bib": {"title": "P-663 Nuclear survivin predicts relapse and poor survival of resectednon-small-cell lung cancer", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:P7Ujq4OLJYoC", "citedby": "0"}, {"bib": {"title": "Regulatory, strategic and methodological issues in the development of targeted anticancer agents: O. 703 INTEGRATING GENOMICS AND PROTEOMICS IN CLINICAL OUTCOMES STUDIES", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:aDl3D7KC1E4C", "citedby": "0"}, {"bib": {"title": "Direct proteomic profiling of clinical samples by MALDI-MS.", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SnGPuo6Feq8C", "citedby": "0"}, {"bib": {"title": "Prostaglandin receptor EP2 but not EP4 inhibits DC migration in tumor-bearing hosts", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:oi2SiIJ9l4AC", "citedby": "0"}, {"bib": {"title": "Generation of adenovirus expressing siRNA to IGF-1R", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:DBa1UEJaJKAC", "citedby": "0"}, {"bib": {"title": "A novel fusion product involving Brd4 from T (15; 19) translocation in human lung cancer including inhibits S-phase progression in vitro", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:SjuI4pbJlxcC", "citedby": "0"}, {"bib": {"title": "Proteomic profiles for predicting response to therapy", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:43bX7VzcjpAC", "citedby": "0"}, {"bib": {"title": "Insulin-like growth factor-I receptor is a candidate molecular target for human esophageal squamous cell cancer.", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PVgj2kMGcgYC", "citedby": "0"}, {"bib": {"title": "Genetic and Cellular Vaccines", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:48xauSegjOkC", "citedby": "0"}, {"bib": {"title": "Integrating genomics and proteomics in clinical outcomes studies", "year": "2005"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:6yz0xqPARnAC", "citedby": "0"}, {"bib": {"title": "Proteomic Profiles Diagnostic For Malignant Pleural Effusions", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:gKiMpY-AVTkC", "citedby": "0"}, {"bib": {"title": "Surviving as a therapeutic target and biomarker for non-small-cell lung cancer", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:nZcligLrVowC", "citedby": "0"}, {"bib": {"title": "Receptor selective retinoids promote monocyte (Mo) differentiation to mature dentritic cells (DC) in peripheral blood of cancer patients", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:mlAyqtXpCwEC", "citedby": "0"}, {"bib": {"title": "Clinical targeting of VEGF and EGFR effective in non-small cell lung cancer", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:6ZzL7HXColQC", "citedby": "0"}, {"bib": {"title": "VEGF receptors and inhibitory effect of VEGF in differentiation of dendritic cells", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:YlPif8NxrbYC", "citedby": "0"}, {"bib": {"title": "The biology of Notch3 signalling pathway in human lung cancers", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HhcuHIWmDEUC", "citedby": "0"}, {"bib": {"title": "Serum proteomic patterns for the diagnosis of lung cancer.", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:O0nohqN1r9EC", "citedby": "0"}, {"bib": {"title": "Proteomic profiles from fine needle aspirates of lung tumors", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:6bLC7aUMtPcC", "citedby": "0"}, {"bib": {"title": "Blockade of insulin-like growth factor signaling induces apoptosis and reduces tumorigenesis and tumor progression in gastric cancer.", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:fbc8zXXH2BUC", "citedby": "0"}, {"bib": {"title": "Conditionally replicating adenovirus can potentiate the effect of adenovirus-p27 gene therapy on lung cancer.", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:3htObqc8RwsC", "citedby": "0"}, {"bib": {"title": "Cloning a rare t (15; 19) translocation in human lung cancer including a novel fusion product involving Brd4", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:OR75R8vi5nAC", "citedby": "0"}, {"bib": {"title": "Cancer-associated immunodeficiency and dendritic cell dysfunction regulated by PGE2-EP2 signaling.", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HtS1dXgVpQUC", "citedby": "0"}, {"bib": {"title": "Experimental Therapeutics, Molecular Targets, and Chemical Biology-Combination Therapy with Conditionally Replicating Adenovirus and Replication Defective Adenovirus", "year": "2004"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ce2CqMG-AY4C", "citedby": "0"}, {"bib": {"title": "O-184 Bronchioalveolar carcinoma: Clinical characteristics and tissue microarray patterns", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:F2UWTTQJPOcC", "citedby": "0"}, {"bib": {"title": "Methods and compositions for the stimulation of human immunodeficiency virus-specific cytotoxic T lymphocytes employing autologous antigen-peripheral blood mononuclear cells", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:RfUwGJFMQ-0C", "citedby": "0"}, {"bib": {"title": "986 Immunization with mutant p53-and K-ras-derived peptides in cancer patients: Immune responses and clinical outcome", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:DrR-2ekChdkC", "citedby": "0"}, {"bib": {"title": "ORIGINAL REPORTS-Lung Cancer-Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib Plus Carboplatin and Paclitaxel in Patients With Stage IIIB \u2026", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:MhiOAD_qIWkC", "citedby": "0"}, {"bib": {"title": "Experimental Therapeutics, Molecular Targets, and Chemical Biology-Genetic Blockade of the Insulin-like Growth Factor-I Receptor: A Promising Strategy for Human Pancreatic Cancer.", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:LgRImbQfgY4C", "citedby": "0"}, {"bib": {"title": "Lung cancer molecular fingerprinting: Expression profiling of gene and protein with cdna microarray and MALDI-TOF MS", "year": "2003"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:vDZJ-YLwNdEC", "citedby": "0"}, {"bib": {"title": "Dendritic cell dysfunction in cancer", "year": "2002"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:GYcXSSpN504C", "citedby": "0"}, {"bib": {"title": "Lung cancer molecular fingerprinting: expression profiling of gene and protein with cDNA microarray and MALDI-TOF MS", "year": "2002"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:NxmKEeNBbOMC", "citedby": "0"}, {"bib": {"title": "Application of Genomics and Proteomics to Developments of Novel Therapies for Lung Cancer", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:7BrZ7Jt4UNcC", "citedby": "0"}, {"bib": {"title": "VEGF as a mediator of tumor-associated defects in T cell development", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:cWzG1nlazyYC", "citedby": "0"}, {"bib": {"title": "Experimental Therapeutics, Preclinical Pharmacology-Dendritic Cells Transduced with Full-Length Wild-Type p53 Generate Antitumor Cytotoxic T Lymphocytes from Peripheral Blood \u2026", "year": "2001"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:1taIhTC69MYC", "citedby": "0"}, {"bib": {"title": "Balanced translocations involving chromosome 19 p in human lung cancer associated with overexpression of Notch3", "year": "2000"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:aIdbFUkbNIkC", "citedby": "0"}, {"bib": {"title": "Objective responses from adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma (BAC)", "year": "2000"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:UuEBAcK4md4C", "citedby": "0"}, {"bib": {"title": "H1 degrees histone and differentiation of dendritic cells (DC). Possible target for tumor-derived factors.", "year": "2000"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:9c2xU6iGI7YC", "citedby": "0"}, {"bib": {"title": "Genetic Subunit Vaccines", "year": "2000"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ALROH1vI_8AC", "citedby": "0"}, {"bib": {"title": "Gene-immunotherapy using dendritic cells", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:WC9gN4BGCRcC", "citedby": "0"}, {"bib": {"title": "Tumor factors and Dendritic cell differentiation.", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:yFnVuubrUp4C", "citedby": "0"}, {"bib": {"title": "The role of CD8+ CTL lytic activity and interferon-gamma production in tumor regression and CD4 T cells in facilitating recurrence of tumor resistant to CTL", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Xl6nMSl579sC", "citedby": "0"}, {"bib": {"title": "CELLULAR IMMUNOLOGY AND IMMUNE REGULATION-A Model for CD8+ CTL Tumor Inummosurveillance and Regulation of Tumor Escape by CD4 T Cells Through an Effect on Quality of CTL", "year": "1999"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:k_7cPK9k7w8C", "citedby": "0"}, {"bib": {"title": "Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoietic progenitors.", "year": "1998"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:IsPWOBWtZBwC", "citedby": "0"}, {"bib": {"title": "Paraneoplastic Host Immune Dysfunction", "year": "1998"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:CaZNVDsoPx4C", "citedby": "0"}, {"bib": {"title": "Intensive radiation therapy concurrent with up to 7-week continuous-infusion paclitaxel for locally advanced solid tumors: Phase I studies (vol 24, pg 81, 1997)", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:mNrWkgRL2YcC", "citedby": "0"}, {"bib": {"title": "Solid phase peptide synthesis. Solid phase peptide synthesis., 1984", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:KWzIFqRkAKkC", "citedby": "0"}, {"bib": {"title": "Leucocyte Typing IV: White Cell Differentiation Antigens. Leucocyte Typing IV: White Cell Differentiation Antigens., 1989", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:JWITY9-sCbMC", "citedby": "0"}, {"bib": {"title": "The Molecular Biology of Lung Cancer", "year": "1997"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:otzGkya1bYkC", "citedby": "0"}, {"bib": {"title": "Candidate cancer vaccines: Oncogenic mutations in RAS create HLA-A2. 1 binding peptides", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:nVrZBo8bIpAC", "citedby": "0"}, {"bib": {"title": "Interleukin 2 Production in Vitroby Peripheral Lymphocytes in Response to Human Papillomavirus-derived Peptides: Correlation with Cervical Pathology", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:DkZNVXde3BIC", "citedby": "0"}, {"bib": {"title": "Adenovirus-based p53 gene therapy in ovarian cancer", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:KNjnJ3z-R6IC", "citedby": "0"}, {"bib": {"title": "Gene therapy for lung cancer", "year": "1996"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:XUvXOeBm_78C", "citedby": "0"}, {"bib": {"title": "NOVEL POLYMORPHISMS OF HUMAN TAP GENES IN HUMAN CANCERS", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:fFSKOagxvKUC", "citedby": "0"}, {"bib": {"title": "Cancer Gene Therapy with Adenovirus-murine GM-CSF", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:lg2tdxc6qMwC", "citedby": "0"}, {"bib": {"title": "Analysis of Tumor Suppressor Genes", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:m92CDrhVnKEC", "citedby": "0"}, {"bib": {"title": "lEeearlydete&nofsecondphmaryhmgcancersbysputumimmuoo-staining", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:PkcyUWeTMh0C", "citedby": "0"}, {"bib": {"title": "Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:wKETBy42zhYC", "citedby": "0"}, {"bib": {"title": "Basic biology", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:7wO8s98CvbsC", "citedby": "0"}, {"bib": {"title": "Developing synthetic peptide vaccines for HIV-1", "year": "1995"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:lgwcVrK6X84C", "citedby": "0"}, {"bib": {"title": "Peptide coated dendritic cells as immunogens", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:DXE8ND7PrJAC", "citedby": "0"}, {"bib": {"title": "Potential diagnostic, prognostic, and therapeutic implications of mutations in the p53 tumor suppressor gene in lung cancer", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:bz8QjSJIRt4C", "citedby": "0"}, {"bib": {"title": "MUTANT P53 TUMOR-SUPPRESSOR PROTEIN AS AN IMMUNOTHERAPEUTIC TARGET", "year": "1994"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:wMgC3FpKEyYC", "citedby": "0"}, {"bib": {"title": "Gene therapy of cancer", "year": "1993"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:0aBXIfxlw9sC", "citedby": "0"}, {"bib": {"title": "Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer", "year": "1993"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:rTD5ala9j4wC", "citedby": "0"}, {"bib": {"title": "Molecular Pathogenesis of Lung Cancer", "year": "1991"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:HIFyuExEbWQC", "citedby": "0"}, {"bib": {"title": "Three-dimensional elastic full waveform inversion in a marine environment using multicomponent ocean-bottom cables: a synthetic study", "year": "1982"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ji7lAbPyDbYC", "citedby": "0"}, {"bib": {"title": "New Approaches to SCLC Therapy: From the Laboratory"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:l6Q3WhenKVUC", "citedby": "0"}, {"bib": {"title": "Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients wit h EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN \u2026"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:e84hm74t-eoC", "citedby": "0"}, {"bib": {"title": "EGFR TESTING IN LUNG CANCER"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:rbGdIwl2e6cC", "citedby": "0"}, {"bib": {"title": "IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab+ Chemotherapy"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:XDrR66g3YHsC", "citedby": "0"}, {"bib": {"title": "Our thanks to all those who have helped with this issue of Personalized Medicine. Listed below are authors, referees and others who have kindly given their time, effort and \u2026"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:9shLKfS_uJEC", "citedby": "0"}, {"bib": {"title": "IASLC BOARD OF DIRECTORS"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:4Yq6kJLCcecC", "citedby": "0"}, {"bib": {"title": "IASLC BOARD OF DIRECTORS"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:wUn16MOA3RoC", "citedby": "0"}, {"bib": {"title": "Resuscitating Notch Immune Surveillance in Cancer"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:Og1tA8FjbJAC", "citedby": "0"}, {"bib": {"title": "Unresolved clinical needs for the most effective management of dry eye"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:yY3RG6sOEgwC", "citedby": "0"}, {"bib": {"title": "Molecular Analysis of the HuD Gene Encoding a Paraneoplastic Encephalomyelitis"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:TaaCk18tZOkC", "citedby": "0"}, {"bib": {"title": "Antitumor Effects of an Adenovirus Expressing Antisense Insulin-like Growth Factor I Receptor on Human Lung Cancer Cell Lines"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:JP7YXuLIOvAC", "citedby": "0"}, {"bib": {"title": "505. Blakesley VA, Stannard BS, Kalebic T, Helman LJ, LeRoith D"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:CNPyR2KL9-0C", "citedby": "0"}, {"bib": {"title": "Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:rbm3iO8VlycC", "citedby": "0"}, {"bib": {"title": "Our thanks to all those who have helped with this issue of Personalized Medicine. Listed below are authors, referees and others who have kindly given their time, effort and \u2026"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:VN7nJs4JPk0C", "citedby": "0"}, {"bib": {"title": "Serum Proteomics (VeriStrat\u00ae):: p. 1 of 6"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:CdxZDUztZiMC", "citedby": "0"}, {"bib": {"title": "JMG Unlocked"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:CB2v5VPnA5kC", "citedby": "0"}, {"bib": {"title": "Materials/Methods: Colony formation assays (CFA) in the presence of a PARP inhibitor ABT-888 (0-10 mM) and/or XRT (0-10 Gy) were performed on AdCre-infected primary cortical \u2026"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:ZzlSgRqYykMC", "citedby": "0"}, {"bib": {"title": "Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine"}, "source": "citations", "id_citations": "ryxMek0AAAAJ:_OXeSy2IsFwC", "citedby": "0"}]}